<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Protection against malaria by variants in red blood cell (RBC) genes
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Protection against malaria by variants in red blood cell (RBC) genes
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Protection against malaria by variants in red blood cell (RBC) genes
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David J Roberts, MA, MB, D Phil
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Johanna Daily, MD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evolution of human red blood cell (RBC) genes is intertwined with the history of human malaria infection.
        </p>
        <p>
         Over the course of many millennia, new RBC gene variants that reduce the risk or severity of malaria infection have been selected by evolutionary pressure. The geographical distribution of protective variants is heterogenous across malaria endemic regions. Outside of endemic areas, some protective variants are clinically silent in the heterozygous state but cause potentially serious disease in the homozygous or compound heterozygous state.
        </p>
        <p>
         This topic discusses the relevant RBC genes and their mechanisms of protection against malaria.
        </p>
        <p>
         Details of malaria pathogenesis and the role of immune response genes are presented in separate topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/5703.html" rel="external">
          "Pathogenesis of malaria"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immune response
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/13572.html" rel="external">
          "An overview of the innate immune system"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EVOLUTIONARY SELECTION PRESSURE FROM MALARIA
         </span>
        </p>
        <p class="headingAnchor" id="H1435626341">
         <span class="h2">
          Parasite-human interactions
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Origins and discovery
         </strong>
         – Exposure of human populations to malaria is estimated to have arisen approximately 10,000 years ago with the emergence of agriculture [
         <a href="#rid1">
          1-4
         </a>
         ]. The sources appear to have been crossovers of a
         <em>
          Plasmodium falciparum
         </em>
         -like parasite from gorillas and of a
         <em>
          P. vivax
         </em>
         -like parasite from chimpanzees [
         <a href="#rid5">
          5,6
         </a>
         ]. Most of the protective RBC genetic variations in human populations, including the sickle cell variant, have been selected during the last 3000 to 11,000 years [
         <a href="#rid1">
          1,7-9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The influence of inherited factors on malaria risk was initially observed in a study of malaria in North America in 1887, which noted the apparent resistance to malaria of those of African descent, who "better than any other resist (malaria's) action" [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Subsequently, the "malaria hypothesis" or "Haldane hypothesis" was published in the 1940s, followed by accumulating evidence for many genetic changes providing protection from
         <em>
          P. falciparum
         </em>
         malaria [
         <a href="#rid11">
          11,12
         </a>
         ]. The "malaria hypothesis" is thought to have been based on the evolving descriptions of the global distribution of beta thalassemia; as described by Haldane in a 1949 publication: "
         <em>
          The corpuscles of the anaemic heterozygotes are smaller than normal, and more resistant to hypotonic solutions. It is at least conceivable that they are also more resistant to attacks by the sporozoa which cause malaria, a disease prevalent in Italy, Sicily, and Greece, where the gene is frequent
         </em>
         " [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selection pressure
         </strong>
         – In theory, all of the human malaria species (
         <em>
          P. falciparum
         </em>
         ,
         <em>
          ovale
         </em>
         ,
         <em>
          vivax
         </em>
         ,
         <em>
          malariae,
         </em>
         and
         <em>
          knowlesi)
         </em>
         can cause selective pressure on the human population; evolutionary selection pressure has been most studied for
         <em>
          P. falciparum
         </em>
         infection [
         <a href="#rid13">
          13,14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5703.html" rel="external">
          "Pathogenesis of malaria", section on 'Genetic factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Gene frequencies &gt;1 percent imply positive selective pressure [
         <a href="#rid13">
          13,15
         </a>
         ]. Besides genetic background, protection comes from prior malaria infections, environmental factors, as well as immune status; it is also modulated by determinants of parasite virulence.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A study from Sri Lanka of the relative importance of genetic and acquired factors on the burden of malaria found that 20 percent of the variability in disease intensity was explained by differences in patient susceptibility to clinical disease [
         <a href="#rid16">
          16
         </a>
         ]. Approximately one-half of the susceptibility differences were attributable to host genes, and one-half were due to age, sex, occupation, and local preventive measures or transmission patterns.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A similar analysis in Africa demonstrated 25 percent of the variation in hospital admission for malaria was explained by the additive effect of multiple protective host genetic variants [
         <a href="#rid17">
          17
         </a>
         ]. Only 2 percent of this variation was due to the sickle cell trait; this suggests that other, largely undefined genetic resistance traits play an important role.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A study from 2020 suggested approximately one-third of the variability in the risk of severe and complicated malaria is explained by additive host genetic effects [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H791396829">
         <span class="h2">
          Categories of protective mechanisms
         </span>
        </p>
        <p class="headingAnchor" id="H505407580">
         <span class="h3">
          Parasite life cycle disruption
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Plasmodium falciparum
         </em>
         malaria, the deadliest form of malaria, has a life cycle that includes a sexual cycle in the insect vector (a female
         <em>
          Anopheles
         </em>
         mosquito) and a human cycle that includes a liver stage and an erythrocytic (RBC, bloodstream) stage  (
         <a class="graphic graphic_figure graphicRef58397" href="/z/d/graphic/58397.html" rel="external">
          figure 1
         </a>
         ). Genetic resistance is much better defined for the RBC stage. (See
         <a class="local">
          'RBC gene alteration'
         </a>
         below.)
        </p>
        <p>
         Mechanisms of protection can occur at the stage of parasite invasion, growth, sequestration (which prevents splenic clearance and contributes to severe disease), and clearance. Some genetic variants can be protective at more than one stage. As an example, alterations in RBC surface proteins and cytoskeletal proteins generally affect parasite entry into the RBC, although they may also play a role in sequestration. Hemoglobin and enzyme alterations generally affect parasite growth within the RBCs, sequestration, and/or clearance of infected RBCs from the circulation. Together these variants often result in decreased parasite biomass and reduce severe malaria.
        </p>
        <p>
         The following summarizes stages of RBC infection and protective genetic changes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Merozoite entry into the cell
         </strong>
         – Malarial invasion of the RBC is a complex, multistep process involving initial nonspecific attachment of the merozoite to the RBC, reorientation of the merozoite so its apical region opposes the RBC membrane, and then zipper-type introjection of the merozoite into the RBC [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           P. falciparum
          </em>
         </strong>
         <strong>
          uses multiple receptors
         </strong>
         – The
         <em>
          falciparum
         </em>
         parasite has multiple redundant pathways, with different parasite ligands and host RBC receptors for different steps of the process of invasion. These include [
         <a href="#rid2">
          2,21
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Glycophorin A of the MNS blood group system. (See
         <a class="local">
          'MNS blood group system (glycophorins A and B)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Glycophorin C, part of the Gerbich blood group system, binds
         <em>
          P. falciparum
         </em>
         erythrocyte binding antigen (EBA)-140, an invasion protein with Duffy-binding like domains (DBLs) [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="local">
          'Gerbich blood group (glycophorin C)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Many more functional EBA proteins have been found in
         <em>
          P. falciparum
         </em>
         merozoites, including erythrocyte-binding antigen-175 (EBA-175); erythrocyte-binding antigen-181 (EBA-181); erythrocyte-binding ligand-1 (EBL-1) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         ABO, Knops, and Ok blood groups also affect parasite entry, but the association of human genetic variants with inhibition of invasion through the respective pathways is less well understood [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="local">
          'ABO blood group system'
         </a>
         below and
         <a class="local">
          'Knops blood group (complement receptor 1)'
         </a>
         below and
         <a class="local">
          'Ok blood group antigen (basigin)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Parasite ligands at the apical region establish specific and high binding affinity interactions mediated by ligands from the erythrocyte-binding-like (EBL) or the reticulocyte-binding homologous protein (PfRh) families, which are able to deform the RBC membrane [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           P. vivax
          </em>
         </strong>
         <strong>
          uses the Duffy antigen
         </strong>
         – Invasion of RBCs by
         <em>
          vivax
         </em>
         malaria merozoites is almost completely dependent on the Duffy blood group antigen [
         <a href="#rid25">
          25,26
         </a>
         ]. (See
         <a class="local">
          'Duffy blood group system'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intracellular parasite growth
         </strong>
         – Parasite growth inside the RBC requires a favorable intracellular environment. Variants that reduce parasite growth include altered hemoglobins (Hbs) including Hb S, Hb C, and Hb E; thalassemias; membrane disorders such as Southeast Asian ovalocytosis and some forms of hereditary elliptocytosis; and enzyme deficiencies such as glucose-6-phosphate dehydrogenase (G6PD) deficiency; and others [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="local">
          'Hemoglobinopathies'
         </a>
         below and
         <a class="local">
          'RBC cytoskeletal changes'
         </a>
         below and
         <a class="local">
          'RBC enzyme deficiencies'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other aspects of infection
         </strong>
         – Other aspects of infection that might be affected include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         RBC lysis at the end of parasite maturation, leading to release of merozoites into the bloodstream
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immune response and phagocytosis of parasite-infected red cells [
         <a href="#rid28">
          28-31
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cytoadherence of infected erythrocytes to endothelial cells, uninfected RBCs, platelets, or antigen-presenting cells
        </p>
        <p>
        </p>
        <p>
         The association of HLA class I allotypes with protection from malaria suggests genetic traits conferring resistance also exist during the hepatic stage of infection [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H688655753">
         <span class="h3">
          RBC gene alteration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parasitization with P
         <em>
          . falciparum
         </em>
         induces a loss of RBC deformability [
         <a href="#rid34">
          34,35
         </a>
         ]. This effect is more prominent in more mature forms (trophozoites and schizonts) and can induce microvascular occlusion (contributing to the ischemic complications of severe falciparum malaria) as well as the clearance of parasitized cells by the reticuloendothelial system.
        </p>
        <p>
         Alterations in various RBC genes can be protective against malaria, including genes that encode [
         <a href="#rid36">
          36
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cell surface proteins, many of which are blood group antigens
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytoskeletal proteins
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemoglobin
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enzymes
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3654630245">
         <span class="h1">
          RBC SURFACE PROTEINS
         </span>
         <span class="headingEndMark">
          —
         </span>
         RBC surface proteins that affect the risk of developing malaria likely do so by preventing entry of the parasite into the RBC. The best described are the Duffy blood group determinants and the glycophorins; there is also increasing evidence for the role of other blood group systems such as ABO, Knops, and Ok.
        </p>
        <p class="headingAnchor" id="H3978466025">
         <span class="h2">
          Duffy blood group system
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           ACKR1
          </em>
         </strong>
         <strong>
          gene and Duffy antigens
         </strong>
         – The Duffy blood group system includes five antigens, two of which are codominant alleles (Fy
         <sup>
          a
         </sup>
         and Fy
         <sup>
          b
         </sup>
         ) that differ by a change at nucleotide 306: guanine in Fy
         <sup>
          a
         </sup>
         and adenine in Fy
         <sup>
          b
         </sup>
         [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Both
         <sup>
         </sup>
         Fy
         <sup>
          a
         </sup>
         and
         <sup>
         </sup>
         Fy
         <sup>
          b
         </sup>
         reside in a glycoprotein of approximately 40 kD known as the Duffy antigen receptor for chemokines (DARC, CD234), which acts as a receptor for certain proinflammatory cytokines (eg, IL-8, monocyte chemotactic protein-1, RANTES) [
         <a href="#rid38">
          38,39
         </a>
         ]. The gene that encodes the receptor is
         <em>
          ACKR1
         </em>
         (previously called
         <em>
          FY
         </em>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'Duffy blood group system'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duffy-null phenotype
         </strong>
         – Duffy antigen negativity corresponds to a null genotype in which neither the Fy
         <sup>
          a
         </sup>
         nor Fy
         <sup>
          b
         </sup>
         antigen is expressed, also designated as Fy(a-b-). Most Duffy-negative people of African descent have a silent Fy
         <sup>
          b
         </sup>
         allele with a single nucleotide substitution that impairs promoter activity in erythroid cells [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The proportion of the population with the Fy(a-b-) phenotype reaches 100 percent in much of Sub-Saharan Africa. It seems that its selective advantage (resistance to invasion by the merozoites
         <em>
          of P. vivax
         </em>
         ) has driven this phenotype nearly to fixation. In Gambian individuals, for example, 100 percent are Duffy negative [
         <a href="#rid41">
          41
         </a>
         ]. This trait is also seen in many other African populations [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The
         <em>
          ACKR1
         </em>
         variant that causes the Duffy-null phenotype is also associated with a lower baseline neutrophil count. (See
         <a class="medical medical_review" href="/z/d/html/139725.html" rel="external">
          "Gene test interpretation:
          <i>
           ACKR1
          </i>
          (Duffy blood group gene)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">
          "Overview of neutropenia in children and adolescents", section on 'Normal variants'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">
          "Approach to the adult with unexplained neutropenia", section on 'Definitions and normal values'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           P. vivax
          </em>
         </strong>
         <strong>
          resistance
         </strong>
         – The Duffy-null phenotype confers protection against
         <em>
          P. vivax
         </em>
         infection, although infection can still occur. A 2022 systematic review and meta-analysis of studies from African countries determined that Duffy-null individuals had a reduced risk of
         <em>
          P. vivax
         </em>
         infection (odds ratio [OR] 0.46, 95% CI 0.26-0.82 [
         <a href="#rid44">
          44
         </a>
         ]. Another study comparing the Fy
         <sup>
          a
         </sup>
         versus Fy
         <sup>
          b
         </sup>
         phenotype found that Fy
         <sup>
          a
         </sup>
         individuals had a reduced risk of
         <em>
          P. vivax
         </em>
         infection relative to Fy
         <sup>
          b
         </sup>
         individuals [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The role of the Duffy blood group system
         <em>
          in P. vivax
         </em>
         infection has been evaluated in several ways:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Human volunteers
         </strong>
         – In a 1958 study in which human volunteers were exposed to mosquitoes infected with
         <em>
          P. vivax
         </em>
         (before in vitro malaria cultures were available), Duffy-negative individuals were resistant to infection, while controls developed malaria 11 to 15 days after exposure [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Epidemiologic studies
         </strong>
         – Epidemiologic studies have shown that Duffy-null individuals are protected from
         <em>
          P. vivax
         </em>
         infection, including soldiers in Vietnam and in children in Papua New Guinea [
         <a href="#rid43">
          43,47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory studies
         </strong>
         – Duffy-null RBCs were first shown to be resistant to invasion by the merozoites of the simian parasite
         <em>
          Plasmodium knowlesi
         </em>
         , which is immunologically related to
         <em>
          P. vivax
         </em>
         [
         <a href="#rid48">
          48,49
         </a>
         ]. Proteins from the two species share sequence homology, and a homologous cysteine-rich domain binds to RBCs [
         <a href="#rid25">
          25
         </a>
         ]. Subsequent studies using blocking antibodies against Duffy antigens (Fy6) or ligands (IL-8; CXCL1, previously called melanoma growth stimulatory activity) demonstrated reduced parasite invasion of RBCs [
         <a href="#rid50">
          50-52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Platelet factor 4 (PF4)
         </strong>
         – PF4 released during platelet activation has been implicated in the killing of parasites within RBCs. PF-4 appears to bind to infected RBCs via the Duffy antigen. These in vitro phenomena suggest somewhat paradoxically that Duffy negative individuals would be at a disadvantage when infected with
         <em>
          P. falciparum
         </em>
         malaria due to lack of PF4 binding [
         <a href="#rid53">
          53
         </a>
         ]. The role of this pathway of parasite killing in patients with malaria remains to be determined.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <strong>
          <em>
           P. vivax
          </em>
         </strong>
         <strong>
          Duffy-binding protein
         </strong>
         <strong>
          (PvDBP)
         </strong>
         – The RBC binding domain in PvDBP is highly variable [
         <a href="#rid54">
          54
         </a>
         ]. The binding domains within the PvDBP lie within a conserved N- terminal cysteine-rich region of 330 amino acids [
         <a href="#rid55">
          55,56
         </a>
         ]. Recombinant proteins have been developed that stimulate blocking antibodies and can prevent RBC invasion [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lessons from vaccine development
         </strong>
         – Vaccination with PvDBP was used to identify an antibody with neutralizing activity against all tested strains of
         <em>
          P. vivax
         </em>
         [
         <a href="#rid58">
          58
         </a>
         ]. Other groups have identified regions of PvDBP that may be useful for vaccine development [
         <a href="#rid59">
          59-62
         </a>
         ]. Duffy binding domains also show sequence conservation with the RBC binding domain of
         <em>
          P. falciparum
         </em>
         EBA-175, suggesting the possibility of a functionally significant structure that could serve as a vaccine candidate [
         <a href="#rid21">
          21,26
         </a>
         ]. (See
         <a class="local">
          'Categories of protective mechanisms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Malaria vaccine development is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5702.html" rel="external">
          "Malaria: Epidemiology, prevention, and control", section on 'Vaccination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2939472735">
         <span class="h2">
          MNS blood group system (glycophorins A and B)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The glycophorins act as receptors for several malarial ligands [
         <a href="#rid23">
          23
         </a>
         ]. Glycophorins A and B are responsible for MNS blood group antigens. (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'MNS blood group system'
         </a>
         .)
        </p>
        <p>
         Engagement of glycophorins may change RBC deformability to permit parasite invasion of the RBC [
         <a href="#rid63">
          63
         </a>
         ]. There are 15 O-glycosidically linked oligosaccharides on each molecule of glycophorins A, B, and C. The capacity of malarial parasites to invade cells with modified O-linked saccharides is reduced [
         <a href="#rid64">
          64-70
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glycophorin A
         </strong>
         – Increasing evidence suggests that some glycophorin A variants are protective against
         <em>
          P. falciparum
         </em>
         malaria.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glycophorin B
         </strong>
         – There is also experimental evidence that S-s-U- RBCs, deficient in glycophorin B, are relatively resistant to malarial invasion. The blood group S-s-U- is found in 2 to 5 percent of people from Africa, suggesting malaria may have provided a selective force for this polymorphism [
         <a href="#rid71">
          71
         </a>
         ]. There is also wide variation in the expression level of glycophorin B, which may be associated with susceptibility to malaria [
         <a href="#rid72">
          72
         </a>
         ]. The parasite ligand for glycophorin B has been identified as the
         <em>
          P. falciparum
         </em>
         erythrocyte binding ligand-1 (EBL-1) [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In a study that evaluated invasion of two different malarial strains, the efficiency of RBC invasion was 20 percent of control in those lacking glycophorin A and 50 percent of control in those lacking glycophorin B [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         Complex polymorphisms affecting the glycophorins, such as the Dantu+ (NE type) blood group phenotype, are associated with reduced susceptibility to severe malaria and reduced parasite growth in RBCs.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dantu blood group and DUP4 structural variant
         </strong>
         – A novel malaria resistance locus was reported close to the cluster of genes encoding glycophorins that provided 33 percent protection against severe malaria (OR 0.67, 95% CI 0.60-0.76) [
         <a href="#rid75">
          75
         </a>
         ]. Genome sequencing demonstrated complex copy number variants (CNVs) at this locus [
         <a href="#rid76">
          76
         </a>
         ]. Eight deletions and eight duplications were found, as well as 11 single nucleotide variants in the glycophorin region. The combined allele frequency of glycophorin CNVs in African populations was 11 percent compared with 1.1 percent in non-African populations. One of the imputed CNVs, DUP4, is associated with decreased risk of severe malaria (OR 0.60, 95% CI 0.50-0.72), reducing the risk of both cerebral malaria and severe malarial anemia. The DUP4 structural variant encodes a fusion protein in which the extracellular domain of glycophorin B is joined to the transmembrane and intracellular domains of glycophorin A, creating the Dantu+ (NE type) blood group phenotype. Parasite growth is impaired in Dantu+ RBCs, consistent with the genetic epidemiology that the
         <em>
          DUP4
         </em>
         variant encoding the Dantu+ NE blood group antigen is associated with protection from malaria [
         <a href="#rid76">
          76,77
         </a>
         ]. The Dantu blood group may limit parasite invasion by increasing RBC membrane tension [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H54122819">
         <span class="h2">
          Gerbich blood group (glycophorin C)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glycophorin C and D carry the Gerbich (Ge) blood group system. Glycophorin C is a receptor for
         <em>
          P. falciparum
         </em>
         erythrocyte-binding antigen 140 (EBA-140, BAEBL), a protein with Duffy-binding-like domains (DBLs) [
         <a href="#rid79">
          79
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'Gerbich blood group system'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiologic evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals who are negative for glycophorin C appear to have a lower risk of malaria. In a survey of 266 individuals from Melanesia, the prevalence of
         <em>
          P. falciparum
         </em>
         and/or
         <em>
          P. vivax
         </em>
         infection was 6 percent in Gerbich-negative individuals, versus 19 percent in Gerbich-positive individuals;
         <em>
          Plasmodium malariae
         </em>
         infection was not affected (8 percent in both groups) [
         <a href="#rid80">
          80
         </a>
         ]. However, other studies have not found differences in either
         <em>
          P. falciparum
         </em>
         or
         <em>
          P. vivax
         </em>
         infection in individuals with glycophorin C deficiency [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Deletion of exon 3 in the glycophorin C gene is seen at a frequency of 47 percent in coastal Papua New Guinea, where malaria is hyperendemic [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanistic evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A protein complex containing protein 4.1, glycophorin C, and p55 appears to be important for
         <em>
          P. falciparum
         </em>
         invasion and development [
         <a href="#rid82">
          82-84
         </a>
         ]. The EBA-140/BAEBL allele containing threonine rather than lysine at position 121, which creates the amino acid sequence VSTK rather than VSKK, can bind to glycophorin C [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The 4.1 protein is also involved in the binding to
         <em>
          P. falciparum
         </em>
         erythrocyte membrane protein-1 (PfEMP1), a protein involved in adhesion of malaria-infected RBC to the vascular endothelium [
         <a href="#rid85">
          85,86
         </a>
         ]. This may contribute to the mechanism of protection in hereditary elliptocytosis. (See
         <a class="local">
          'Hereditary elliptocytosis (HE)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H407495488">
         <span class="h2">
          ABO blood group system
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ABO blood group system is defined by carbohydrates (sugars) that are added on top of the carbohydrate backbone known as the "H" antigen. The glycosyltransferase enzymes responsible for adding these sugars are encoded by the
         <em>
          ABO
         </em>
         gene. (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'ABO blood group system'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiologic evidence
         </strong>
         – Two studies, including a large study of 9000 children, have shown that blood group O confers protection against malaria (OR 1.2, 95% CI 1.09-1.32) [
         <a href="#rid27">
          27,87,88
         </a>
         ]. Two additional studies have suggested that group A red cells are associated with severe malaria [
         <a href="#rid89">
          89,90
         </a>
         ]. These observations are consistent with the low frequency of blood group A in many endemic malarial areas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanistic evidence
         </strong>
         – Possible mechanisms for the protective effect of group O blood type include the modulation of rosetting of uninfected RBCs by infected RBCs as well as the adherence of infected RBCs to host receptors on monocytes, platelets, and endothelium [
         <a href="#rid88">
          88
         </a>
         ]. This effect has been exhibited by some
         <em>
          P. falciparum
         </em>
         strains in vitro [
         <a href="#rid91">
          91,92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical evidence from Thailand and East Africa has supported the role for the influence of rosetting by ABO blood group type. In these studies the frequency of rosetting parasites was less in blood isolated from Group O patients than from patients with blood groups A, B, and AB [
         <a href="#rid93">
          93-95
         </a>
         ]. The association of blood group O with protection and with reduced rosetting has also been confirmed in a large case control study of malaria [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         ABO blood group polymorphisms also modulate sialic acid recognition by some pathogen receptors and may alter the rate of phagocytosis of infected RBCs [
         <a href="#rid97">
          97
         </a>
         ]; it remains unclear if these phenomena are mechanisms of protection in malaria [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         It has been suggested that during exchange transfusion for resistant
         <em>
          P. falciparum
         </em>
         , it may be appropriate to consider the ABO blood group of the transfused cells in treatment planning [
         <a href="#rid99">
          99
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">
          "Treatment of severe malaria", section on 'Exchange transfusion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4274339215">
         <span class="h2">
          Knops blood group (complement receptor 1)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Knops blood group system is controlled by the
         <em>
          CR1
         </em>
         gene, which encodes complement receptor 1 (CR1), also called CD35 [
         <a href="#rid100">
          100
         </a>
         ]. Knops antigens include McCoy (McC) and Swain-Langley (Sl). (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'Knops blood group system'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiologic evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children with certain Knops genotypes were less likely to have cerebral malaria (OR 0.17, 95% CI 0.04-0.72) than children with Sl(1/1) [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A study from Ghana showed that the McC
         <sup>
          b/b
         </sup>
         genotype was associated with a reduced risk of severe malaria (OR for severe malaria relative to uncomplicated malaria 0.12, 95% CI 0.02-0.64, p = 0.013); heterozygosity (McC
         <sup>
          a/b
         </sup>
         ) was associated with increased susceptibility to severe malaria (OR for severe malaria relative to uncomplicated malaria 2.31, 95% CI 1.03-5.20) [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A case control study from Kenya found that the Sl2 polymorphism was associated with reduced odds of cerebral malaria and death, while the McC
         <sup>
          b
         </sup>
         polymorphism was associated with increased odds of cerebral malaria [
         <a href="#rid103">
          103
         </a>
         ]. The protective association of Sl2 was greatest in children with normal alpha globin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These complex associations may explain some previous studies that did not show an association of CR1 alleles with protection from malaria [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanistic evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CR1 is the sialic acid-independent receptor used by
         <em>
          P. falciparum
         </em>
         to invade RBCs [
         <a href="#rid105">
          105
         </a>
         ]. CR1 may also be a receptor during invasion by
         <em>
          P. vivax
         </em>
         merozoites [
         <a href="#rid106">
          106
         </a>
         ]. T
         <em>
          he P. falciparum
         </em>
         adhesin PfRh4 binds to CR1 at the complement control protein modules 1 to 3 (CCP1-3); this is the region of CR1 that binds to complement components C4b and C3b [
         <a href="#rid107">
          107
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3968.html" rel="external">
          "Complement pathways"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CR1 has been implicated in rosetting of uninfected RBCs
         <em>
          to P. falciparum
         </em>
         -infected cells, a phenomenon associated with severe malaria [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H206769880">
         <span class="h2">
          Ok blood group antigen (basigin)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ok blood group antigens are not obviously polymorphic in malaria endemic regions.
        </p>
        <p>
         However, the Ok blood group antigen basigin has been identified as a receptor for PfRh5, a parasite ligand that is essential for blood stage growth. RBC invasion was inhibited by soluble basigin or by basigin knockdown, and invasion could be completely blocked using low concentrations of anti-basigin antibodies across all laboratory strains [
         <a href="#rid109">
          109
         </a>
         ]. Furthermore, Ok(a-) RBCs, which express a basigin variant that has a weaker binding affinity for PfRh5, had reduced invasion efficiencies.
        </p>
        <p>
         PfRh5 forms a complex with the
         <em>
          P. falciparum
         </em>
         proteins CyRPA and Ripr when interacting with basigin [
         <a href="#rid110">
          110
         </a>
         ]; PfRh5-basigin interaction triggers remodeling of the RBC cytoskeleton to allow merozoite invasion [
         <a href="#rid111">
          111
         </a>
         ]. Binding of PFRh5 to basigin may be responsible for the species specificity of PfRH5 binding and provide a molecular basis for the restriction of
         <em>
          P. falciparum
         </em>
         to its human host among other primates [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
         These findings have provoked renewed interest in further explorations of PfRh5 as a vaccine candidate antigen. Recombinant PfRh5 can induce antibodies in humans that block invasion of RBCs by merozoites [
         <a href="#rid113">
          113
         </a>
         ]. A recombinant chimeric antibody (Ab-1) against basigin inhibited the PfRH5-basigin interaction and blocked erythrocyte invasion across multiple parasite strains [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1690095088">
         <span class="h2">
          Membrane channels
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preclinical studies have suggested that variants affecting membrane channels might be protective, although further study is needed. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calcium pump ATP2B4
         </strong>
         – A genome-wide association study showed that polymorphisms that map to the major RBC calcium pump (
         <em>
          ATP2B4
         </em>
         ) were associated with protection from severe malaria [
         <a href="#rid27">
          27,115
         </a>
         ]. Erythroid cells with a deletion of the
         <em>
          ATP2B4
         </em>
         enhancer have abnormally high intracellular calcium levels [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ferroportin
         </strong>
         – Ferroportin is an iron transport channel expressed on many cell types including developing and mature RBCs. Ferroportin knockout mice show increased susceptibility to malaria. A common polymorphism (
         <em>
          FPN
         </em>
         Q248H) renders the protein resistant to downregulation by the iron-regulatory hormone hepcidin and reduces intracellular iron accumulation, hemolysis and anemia, although there are conflicting reports on whether it reduces the risk of malaria or the degree of parasitemia [
         <a href="#rid117">
          117,118
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">
          "Regulation of iron balance", section on 'Ferroportin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Piezo1
         </strong>
         – Parasite growth is reduced in dehydrated cells [
         <a href="#rid119">
          119
         </a>
         ]. Gain-of-function mutations in
         <em>
          PIEZO1
         </em>
         , which encodes a mechanically activated ion channel, cause hereditary xerocytosis (HX), which is characterized by RBC dehydration and mild hemolysis. Mice with a germline gain-of-function
         <em>
          PIEZO1
         </em>
         mutation are protected from cerebral malaria with the rodent parasite
         <em>
          Plasmodium berghei
         </em>
         [
         <a href="#rid120">
          120
         </a>
         ]. The same study evaluated a population from Africa and found a gain-of-function
         <em>
          PIEZO1
         </em>
         allele, E756del, in one-third of the participants. RBCs from individuals carrying this allele are dehydrated and display reduced Plasmodium infection in vitro. (See
         <a class="medical medical_review" href="/z/d/html/7068.html" rel="external">
          "Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)", section on 'Control of RBC solute and water content'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3014778523">
         <span class="h1">
          RBC CYTOSKELETAL CHANGES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cytoskeletal changes may affect RBC invasion and/or parasite growth. One possible mechanism by which parasite growth is impaired in protein 4.1-deficient cells is accumulation of a protein that regulates cytoadherence. Other possibilities include involvement of host cytoskeletal proteins in the generation of the parasite membrane or the insertion of parasite proteins into the RBC surface [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H891393747">
         <span class="h2">
          Southeast Asian ovalocytosis (SAO)
         </span>
         <span class="headingEndMark">
          —
         </span>
         SAO is a hereditary condition that results from a specific 27 base pair deletion in the
         <em>
          SLC4A1
         </em>
         gene, which encodes band 3. Band 3 is an integral membrane protein that functions as a chloride-bicarbonate exchanger and provides structural cohesion between the RBC membrane and the underlying spectrin-based cytoskeleton. The SAO variant causes increased RBC rigidity. (See
         <a class="medical medical_review" href="/z/d/html/142822.html" rel="external">
          "Southeast Asian ovalocytosis (SAO)", section on 'Characteristics of RBCs'
         </a>
         .)
        </p>
        <p>
         It is unclear if other Band 3 variants are associated with protection from malaria.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiologic evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Epidemiologic evidence suggests that SAO confers resistance to high levels of parasitemia with
         <em>
          P. falciparum
         </em>
         ,
         <em>
          P. vivax
         </em>
         , and
         <em>
          P. malariae
         </em>
         [
         <a href="#rid122">
          122,123
         </a>
         ]. It may also protect against cerebral malaria in patients infected with
         <em>
          P. falciparum
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the Madang area of Papua New Guinea, heterozygous SAO was present in 15 percent of all inhabitants, 9 percent of those who had uncomplicated
         <em>
          P. falciparum
         </em>
         malaria, and in none of those with potentially life-threatening cerebral malaria [
         <a href="#rid124">
          124
         </a>
         ]. However, the prevalence of SAO did not differ between children with and without acute
         <em>
          P. falciparum
         </em>
         malaria, suggesting that ovalocytosis protects from dying of malaria but not from acquiring malaria [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         SAO is present in approximately 30 percent of the Melanesian population of Papua New Guinea and other aboriginal populations of Southeast Asia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanistic evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In vitro, SAO RBCs are highly resistant to invasion by
         <em>
          P. falciparum
         </em>
         merozoites [
         <a href="#rid126">
          126-128
         </a>
         ]. They are also resistant to invasion by
         <em>
          P. knowlesi
         </em>
         , a plasmodium similar to
         <em>
          P. vivax
         </em>
         [
         <a href="#rid127">
          127
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A similar resistance to
         <em>
          P. knowlesi
         </em>
         invasion can be induced in control RBCs by monoclonal antibodies directed against band 3, the protein that is abnormal in SAO [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Why merozoites are unable to invade the SAO cell is not well understood. Inhibition of invasion of two types of plasmodia suggests involvement of a later stage of invasion than receptor recognition. In vitro studies suggest that it is decreased deformability, not the ovalocytic shape per se, that is of primary importance in protecting against malaria [
         <a href="#rid128">
          128
         </a>
         ]. The degree of impaired invasion is closely related to the degree of reduced deformability [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Malaria infection also induces the generation of ovalocytes. In one series from Thailand, individuals infected with malaria had a higher percent of ovalocytes than uninfected controls (6.3 percent with
         <em>
          P. falciparum
         </em>
         , 8.3 percent with
         <em>
          P. vivax
         </em>
         , and 0.6 percent in uninfected controls) [
         <a href="#rid131">
          131
         </a>
         ]. Infected ovalocytes contained significantly fewer parasites than infected discocytes, suggesting that the development of ovalocytes could represent a host response to parasite multiplication within the circulation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3886045601">
         <span class="h2">
          Hereditary elliptocytosis (HE)
         </span>
         <span class="headingEndMark">
          —
         </span>
         HE is cytoskeletal disorder caused by pathogenic variants in the genes for protein 4.1 (
         <em>
          EPB41
         </em>
         ), alpha spectrin (
         <em>
          SPTA1
         </em>
         ), beta spectrin (
         <em>
          SPTB
         </em>
         ), and glycophorin C (
         <em>
          GYPC
         </em>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7087.html" rel="external">
          "Hereditary elliptocytosis and related disorders", section on 'Gene variants'
         </a>
         and
         <a class="local">
          'Gerbich blood group (glycophorin C)'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiologic evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The prevalence of HE is 2.5 to 5 per 10,000 in the United States but may be &gt;1 to 10 percent in areas in which malaria is endemic [
         <a href="#rid132">
          132-134
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7087.html" rel="external">
          "Hereditary elliptocytosis and related disorders"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanistic evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         HE RBCs demonstrate resistance to invasion by both
         <em>
          P. knowlesi
         </em>
         and
         <em>
          P. falciparum
         </em>
         . The resistance may involve diminished invasion, poor intraerythrocytic growth, or diminished cytoadherence of infected RBCs [
         <a href="#rid135">
          135
         </a>
         ]. In particular, a normal protein 4.1/glycophorin C/p55 complex appears to be important for parasite invasion and development [
         <a href="#rid83">
          83
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7091.html" rel="external">
          "Red blood cell membrane: Structure and dynamics"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Less common structural variants that increase the content of spectrin dimers also exhibit impaired parasite growth [
         <a href="#rid136">
          136
         </a>
         ]. This pattern is distinct from that seen in hereditary spherocytosis (HS), in which parasite growth is diminished in proportion to the reduction in spectrin content [
         <a href="#rid136">
          136
         </a>
         ]. (See
         <a class="local">
          'Hereditary spherocytosis (HS; uncertain role)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A phosphorylated form of protein 4.1 appears during
         <em>
          P. falciparum
         </em>
         growth that is not seen in infected RBCs [
         <a href="#rid137">
          137
         </a>
         ]. The possible role of this phosphoprotein in parasite growth and survival is uncertain.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1545099588">
         <span class="h2">
          Hereditary spherocytosis (HS; uncertain role)
         </span>
         <span class="headingEndMark">
          —
         </span>
         HS is caused by variants in one of five genes for proteins that link the RBC cytoskeleton to the overlying lipid bilayer. Its role in protection against malaria is uncertain. (See
         <a class="medical medical_review" href="/z/d/html/7079.html" rel="external">
          "Hereditary spherocytosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiologic evidence
         </strong>
         – HS has not been reported at increased frequency in regions of the world with increased malaria.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanistic evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In an in vitro study,
         <em>
          P. falciparum
         </em>
         growth in HS erythrocytes showed normal growth for two days, followed by impaired growth, the onset of which was more rapid in cells with greater degrees of spectrin deficiency [
         <a href="#rid136">
          136
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In ankyrin/spectrin deficient mice, spectrin appeared to be necessary for the invasion and/or growth of malarial parasites [
         <a href="#rid121">
          121
         </a>
         ]. Heterozygous ankyrin-1 null mice have wild-type levels of ankyrin-1 and spectrin with normal red cell survival but are nevertheless protected from malaria. Resistance is not due to reduced invasion; the exact mechanism of protection is unclear [
         <a href="#rid138">
          138
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3151318344">
         <span class="h1">
          HEMOGLOBINOPATHIES
         </span>
        </p>
        <p class="headingAnchor" id="H2416584141">
         <span class="h2">
          Hemoglobinopathies overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several case-control and cohort studies have explored the role of specific hemoglobinopathies in resistance to malaria.
        </p>
        <p>
         A 2012 meta-analysis of case-control studies showed a decreased risk (lower odds ratio [OR]) of severe
         <em>
          P. falciparum
         </em>
         malaria in individuals with the following hemoglobins (Hbs) [
         <a href="#rid139">
          139
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hb AS – OR 0.09, 95% CI 0.06-0.12
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hb CC – OR 0.27, 95% CI 0.11-0.63
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hb AC – OR 0.83, 95% CI 0.67-0.96
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Homozygous alpha thalassemia – OR 0.63, 95% CI 0.48-0.83
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heterozygous alpha thalassemia – OR 0.83, 95% CI 0.74-0.92
        </p>
        <p>
        </p>
        <p>
         Only Hb AS showed protection from uncomplicated malaria (incidence rate ratio [IRR] 0.69, 95% CI 0.61-0.79), and none of the hemoglobinopathies were consistently protective against asymptomatic parasitemia [
         <a href="#rid139">
          139
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Sickle cell variant
         </span>
         <span class="headingEndMark">
          —
         </span>
         The sickle cell variant is a single point mutation in the gene that encodes beta globin (
         <em>
          HBB
         </em>
         ). It is thought to have arisen as a founder mutation in Africa thousands of years ago. (See
         <a class="local">
          'Parasite-human interactions'
         </a>
         above.)
        </p>
        <p>
         The point mutation creates an amino acid substitution (valine instead of the normal glutamic acid) at amino acid 7, referred to as p.glu7val; a previous numbering system referred to this as p.glu6val. (See
         <a class="medical medical_review" href="/z/d/html/7135.html" rel="external">
          "Pathophysiology of sickle cell disease", section on 'Sickle hemoglobin'
         </a>
         .)
        </p>
        <p>
         A connection between the epidemiology of the sickle cell variant and the distribution of malaria was observed decades ago, and the suggestion that variant conferred a selection advantage was made as early as the 1940s [
         <a href="#rid140">
          140,141
         </a>
         ].
        </p>
        <p>
         Sickle cell trait (heterozygosity for the variant) is protective without causing significant morbidity. In contrast, sickle cell disease (homozygosity, with Hb SS; or compound heterozygosity with another beta globin variant such as Hb SC or Hb S-beta thalassemia) causes significant morbidity. (See
         <a class="local">
          'Sickle cell trait'
         </a>
         below and
         <a class="local">
          'Sickle cell disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Sickle cell trait
         </span>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h4">
          Epidemiological evidence
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe or fatal infection
         </strong>
         – Case-control studies have demonstrated that sickle cell trait is 90 percent protective against severe and complicated malaria (cerebral malaria and severe anemia) and 60 percent protective against clinical malaria leading to hospital admission [
         <a href="#rid32">
          32,142
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A cohort study has shown that sickle trait confers 60 percent protection against mortality between 2 and 16 months of age in an area of high transmission [
         <a href="#rid14">
          14
         </a>
         ]. There is some evidence for protection against mild clinical malaria, but this generally manifests as reduced parasite densities rather than protection against parasitemia per se [
         <a href="#rid143">
          143-145
         </a>
         ]. Another study showed that sickle cell trait protected individuals with severe
         <em>
          P. falciparum
         </em>
         malaria against hyperparasitemia [
         <a href="#rid146">
          146
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Reducing severe infections may also reduce other complications of malaria:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bacterial superinfection
         </strong>
         – Malaria infection strongly predisposes to bacteremia, often with non-
         <em>
          Salmonella typhi
         </em>
         species. In malaria endemic areas, Hb AS may protect against bacteremia (OR 0.36, 95% CI 0.2-0.65) [
         <a href="#rid147">
          147
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Iron deficiency and malnutrition
         </strong>
         – Hb AS may also confer protection from iron deficiency anemia. Using Mendelian randomization, Hb AS was shown to be associated with a 30 percent reduction in iron deficiency among children living in malaria-endemic countries in Africa, but not among individuals living in malaria-free areas [
         <a href="#rid148">
          148
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Those with Hb AS are also protected from neonatal conditions (perhaps indirectly; OR 0.79, 95% CI 0.67-0.93) and malnutrition (OR 0.67, 95% CI 0.55-0.83) [
         <a href="#rid149">
          149
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild infection and epistasis
         </strong>
         – The most comprehensive longitudinal studies of the role of sickle cell trait in protection from malaria have shown protection from mild disease but negative epistasis (or interaction) between the malaria-protective effects of alpha thalassemia and sickle cell trait. The protection afforded by each condition inherited alone was lost when the two conditions were inherited together, so that the incidence of both uncomplicated and severe
         <em>
          P. falciparum
         </em>
         malaria was close to baseline in children with both Hb AS and homozygosity for alpha
         <sup>
          +
         </sup>
         thalassemia [
         <a href="#rid150">
          150
         </a>
         ]. (See
         <a class="local">
          'Thalassemia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In utero transmission
         </strong>
         – Hb AS does not protect against placental malaria across a range of parasitologic, clinical, and histologic outcomes [
         <a href="#rid151">
          151
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h4">
          Mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanisms by which sickle cell trait protects against
         <em>
          P. falciparum
         </em>
         are not fully understood and may be both innate and acquired [
         <a href="#rid152">
          152,153
         </a>
         ]. Several mechanisms, not mutually exclusive, have been proposed to explain impaired parasite growth or death in deoxygenated sickle trait RBCs or removal of parasites growing in sickle trait RBCs from the circulation [
         <a href="#rid154">
          154-163
         </a>
         ].
        </p>
        <p>
         Some parasite genotypes are found more frequently in people with Hb AS than people with Hb AA, suggesting some parasite traits confer a selective advantage [
         <a href="#rid164">
          164
         </a>
         ]. The Hb S-associated alleles include nonsynonymous variants in the acyl-CoA synthetase family member PfACS8 on chromosome 2 and two other regions of the parasite genome [
         <a href="#rid164">
          164
         </a>
         ]. Understanding the biological mechanisms that confer advantages for some parasite genotypes may help clarify the mechanisms by which Hb AS trait is protective against malaria.
        </p>
        <p>
         Two principal factors are increased sickling and impaired growth of the parasite during vascular sequestration.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increased sickling
         </strong>
         – The first line of defense is an acceleration of sickling rates in parasitized sickle cell trait RBCs that facilitates their removal from the circulation. Studies using cultured parasitized sickle cell trait RBCs at physiologic levels of deoxygenation showed that cells infected with ring forms had accelerated sickling compared with noninfected cells [
         <a href="#rid165">
          165,166
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impaired parasite growth
         </strong>
         –
         <em>
          P. falciparum
         </em>
         growth is impaired in deoxygenated sickle trait cells [
         <a href="#rid167">
          167-169
         </a>
         ]
         <em>
          .
         </em>
         <em>
          P. falciparum
         </em>
         grows normally in infected sickle trait cells exposed to 17 percent oxygen, but reducing the oxygen content to 3 percent results in parasite death within a few days due to formation of sickle hemoglobin [
         <a href="#rid170">
          170,171
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This effect may be more biologically significant in reducing morbidity and mortality from malaria than a reduction in cytoadherence of infected red cells to the endothelium.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The following changes may contribute to impaired parasite growth in sickle cell trait red cells:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Loss of potassium
         </strong>
         – Sickle RBCs have two abnormal mechanisms that facilitate potassium loss. One is the increased activity of the K-Cl cotransporter, due in part to absence of the normal inhibition of the transporter by low oxygen tension, along with retention of its ability to be activated by low pH; both of which occur at sites of stagnant circulation. The second mechanism is increased activity of the calcium-dependent (Gardos) potassium channel, due to a transient increase in cell calcium during sickling [
         <a href="#rid172">
          172-174
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7135.html" rel="external">
          "Pathophysiology of sickle cell disease", section on 'Effects on the RBC'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cellular dehydration
         </strong>
         – The osmotic loss of water that follows the loss of potassium increases the mean cell Hb S concentration and Hb S polymerization. (See
         <a class="medical medical_review" href="/z/d/html/7135.html" rel="external">
          "Pathophysiology of sickle cell disease", section on 'Effects on the RBC'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Parasite growth is normal in RBCs that have a low potassium concentration induced by incubation with ouabain, which inhibits the Na-K-ATPase pump [
         <a href="#rid175">
          175,176
         </a>
         ]. This observation suggests that water loss with promotion of polymerization of Hb S, not a low potassium content, is of primary importance for impairing parasite growth.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          RBC microRNAs
         </strong>
         – A subset of erythrocyte miRNAs translocates into the parasite and reduces the growth of the parasites; this includes miRNAs miR-451 and let-7i, which are enhanced in RBCs containing Hb AS. In experimental systems, transfection of miR-451 and let-7i inhibits parasite growth; these miRNAs form chimeric transcripts with the 5' end of parasite mRNAs and inhibit translation of targeted parasite mRNAs [
         <a href="#rid154">
          154
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Increased phagocytosis
         </strong>
         – There is conflicting experimental evidence for enhanced phagocytosis or retention of ring-stage-infected Hb AS RBCs compared with ring-stage-infected Hb AA RBCs.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In some experimental models, malaria-infected RBCs containing Hb AS are also susceptible to enhanced phagocytosis of ring forms of the parasite [
         <a href="#rid157">
          157
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Membrane-bound hemichromes, autologous immunoglobulin G (IgG) and complement C3c fragments, aggregated band 3, and phagocytosis by human monocytes were greater in rings developing in Hb AS RBCs than in controls, and phagocytosis of ring-parasitized Hb AS RBCs was predominantly complement-mediated. Similar findings were reported for RBCs in beta thalassemia trait and Hb H disease, but not for alpha thalassemia trait erythrocytes [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="local">
          'Thalassemia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         However, other experimental models examining retention of malaria-infected RBCs by microspheres in vitro or human spleens ex vivo have not shown that ring-stage parasites in Hb AS red cells are retained more than ring-stage parasites in Hb AA red cells [
         <a href="#rid157">
          157
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Altered actin polymerization
         </strong>
         – There is substantial evidence for altered actin polymerization in malaria-infected Hb AS cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Hbs S and C affect the trafficking system that directs parasite-encoded proteins to the surface of infected erythrocytes. Hemoglobin oxidation may inhibit actin polymerization and disrupt the actin cytoskeleton and Maurer's clefts (a parasite-derived organelle) [
         <a href="#rid158">
          158
         </a>
         ]. Maurer's clefts moved significantly faster in infected RBCs containing the Hb variants S and C than in infected wild-type erythrocytes due to an impaired actin network in infected erythrocytes [
         <a href="#rid159">
          159
         </a>
         ]. (See
         <a class="local">
          'Hemoglobin C'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Reduced actin polymerization resulted in reduced protein trafficking from the Maurer's clefts, which appears to be due to redox imbalance [
         <a href="#rid160">
          160
         </a>
         ]. Similar reductions in actin polymerization can be shown when Hb AA erythrocytes are exposed to a transient moderate oxidant stress before parasite invasion, suggesting that irreversibly oxidized products, such as ferryl hemoglobin, hemichrome radicals, or ferryl heme interfere with actin reorganization and cytoadhesion [
         <a href="#rid160">
          160
         </a>
         ]. (See
         <a class="local">
          'G6PD deficiency'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Reduced cytoadherence
         </strong>
         – It is possible that reduced adhesion of mature infected RBCs contributes protection in Hb AS RBCs.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Infected RBCs from sickle trait individuals demonstrate reduced in vitro adhesion to microvascular endothelial cells and blood monocytes relative to adhesion of infected Hb AA RBCs. Hb AS RBCs also show reduced expression on their surface of the variant antigen Pf-EMP-
         <em>
          1 (P. falciparum
         </em>
         erythrocyte membrane protein-1), the parasite's major cytoadherence ligand and virulence factor, and reduced adhesion to CD36 and endothelial protein C receptor (EPCR) [
         <a href="#rid161">
          161,177
         </a>
         ]. Sickle RBCs display altered endothelial cell adhesion, and decreased adhesion resulted in less endothelial cell activation [
         <a href="#rid178">
          178
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The relative importance of these phenomena in patients with malaria is unclear.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immune mechanisms
         </strong>
         – A series of intriguing observations suggests that the protection of people with sickle cell trait may be mediated, at least in part, by enhancing the acquired immune response to malaria [
         <a href="#rid163">
          163,179,180
         </a>
         ]. Such an explicit immune-mediated mechanism(s) would explain observations that the effect of Hb AS on parasite density was strongly age-dependent, only beginning after two years [
         <a href="#rid163">
          163
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Two studies have found significantly raised IgG levels in young Hb AS children [
         <a href="#rid181">
          181,182
         </a>
         ]. Children with the Hb AS phenotype had higher levels of anti-sporozoite antibodies and agglutinating antibodies to variant surface antigens [
         <a href="#rid144">
          144
         </a>
         ]. However, the antibody response against a microarray of
         <em>
          P. falciparum
         </em>
         proteins showed no significant difference in antibody responses in children with Hb AS and Hb AA controls [
         <a href="#rid183">
          183
         </a>
         ]. It remains possible that Hb AS and Hb AC may modulate other protective immune responses.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Significantly increased lymphoproliferative responses to malaria antigens have also been seen [
         <a href="#rid184">
          184
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The mechanism of an enhanced immunologic response has not been established but may be due to enhanced removal of ring-stage parasites and/or reduced adhesion of late-stage or mature infected RBCs [
         <a href="#rid185">
          185-187
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mouse models
         </strong>
         – Mice are susceptible to several species of Plasmodia, and a transgenic mouse model recapitulating sickle cell disease (SCD) has allowed new approaches to dissecting the protective mechanisms of malaria [
         <a href="#rid31">
          31,188-190
         </a>
         ]. In studies of sickle transgenic mice,
         <em>
          P. chabaudi adami
         </em>
         ,
         <em>
          P. berghei
         </em>
         , and the
         <em>
          P. yoelii
         </em>
         strains were used in nonlethal and lethal infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         When these mice were infected with two species of rodent malaria, they showed a diminished and delayed increase in parasitemia compared with controls [
         <a href="#rid31">
          31
         </a>
         ]. This benefit in
         <em>
          P. chabaudi adami
         </em>
         infection was completely prevented by splenectomy, suggesting that enhanced removal of malaria-infected Hb AS cells by the spleen is required to mediate protection from malaria.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Sickle cell disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         People with sickle cell anemia (Hb SS), a form of sickle cell disease (SCD), remain susceptible to malaria and may die from volume depletion, acidosis, or cytokine release. (See
         <a class="medical medical_review" href="/z/d/html/7113.html" rel="external">
          "Diagnosis of sickle cell disorders", section on 'Terminology'
         </a>
         .)
        </p>
        <p>
         It is widely believed that malaria is a major risk factor for death among children with SCD, although there is no clear evidence that children with SCD are at greater risk from malaria than children without SCD [
         <a href="#rid191">
          191,192
         </a>
         ]. Children with Hb SS are no more likely to have uncomplicated malaria than controls. Nevertheless, mortality was considerably higher among children with Hb SS than controls with Hb AA or Hb AS children hospitalized with malaria [
         <a href="#rid193">
          193
         </a>
         ]. Children with Hb SS are at higher risk of readmission to the hospital after severe malaria than children with Hb AA [
         <a href="#rid194">
          194
         </a>
         ].
        </p>
        <p>
         Similar results were reported from Tanzania, where parasitemia during the hospitalization of children with SCD was associated with both severe anemia and death [
         <a href="#rid195">
          195
         </a>
         ]. Intermittent preventive treatment with sulfadoxine-pyrimethamine in patients with Hb SS may significantly reduce patients' symptoms and anemia but not vaso-occlusive pain episodes or hospitalization [
         <a href="#rid196">
          196,197
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Hemoglobin C
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hb C is a beta globin (
         <em>
          HBB
         </em>
         ) variant that substitutes lysine for glutamic acid at amino acid 7  (
         <a class="graphic graphic_figure graphicRef131447" href="/z/d/graphic/131447.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7127.html" rel="external">
          "Hemoglobin variants including Hb C, Hb D, and Hb E", section on 'Hb C'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiologic data
         </strong>
         – There is good epidemiological evidence for a protective effect of the heterozygous (Hb AC) state, especially in regard to cerebral malaria [
         <a href="#rid198">
          198,199
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hb C is seen at maximum frequency in northern Burkina Faso; the prevalence decreases concentrically in surrounding areas. A 2001 case-control study involving 4348 Mossi individuals from Burkina Faso suggested a 29 percent reduction in risk of clinical malaria in individuals who were heterozygous for Hb C (Hb AC) and a 93 percent reduction in individuals who were homozygous (Hb CC) [
         <a href="#rid200">
          200
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A case-control study from Ghana reported that children with Hb AC and Hb CC genotypes were protected from severe malaria [
         <a href="#rid201">
          201
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The data for protection against mild malaria for Hb AC heterozygotes are less clear. Two prospective cohort studies from Mali have shown inconsistent results.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A study from Bamako in Mali showed that mild malaria incidence was slightly higher in Hb AC children than in Hb AA children (adjusted IRR 1.15, 95% CI 1.01-1.32) [
         <a href="#rid202">
          202
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A study in the town of Bandiagara in a younger-aged cohort showed fewer episodes of clinical malaria in children with Hb AC compared with Hb AA controls [
         <a href="#rid199">
          199
         </a>
         ]. Hb AC was associated with higher newborn birthweight among following pregnancy-associated malaria, conferring a survival advantage for newborns from Hb AC mothers [
         <a href="#rid203">
          203
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanistic data
         </strong>
         – In vitro studies in oxygenated Hb CC cells have shown the following results [
         <a href="#rid169">
          169
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No abnormality in parasite invasion.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Normal growth during the first growth cycle but a markedly reduced number of ring forms following the schizont stage, with degenerated schizonts observed on day 4. This defect was not affected by deoxygenation or an increase in the extracellular potassium concentration, excluding a potassium leak-dependent mechanism.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Marked resistance to osmotic lysis compared with parasitized normal cells. Thus, these cells cannot burst and release merozoites in a normal fashion.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hb C modulates the cell surface properties of
         <em>
          P. falciparum
         </em>
         -infected erythrocytes by reducing expression of the variant antigen (Pf-EMP-1) [
         <a href="#rid204">
          204
         </a>
         ]. As a result, infected RBCs with Hb AC or Hb CC show reduced adhesion to endothelial cells expressing CD36 and intercellular adhesion molecule-1 (ICAM-1), reduced rosetting with uninfected RBCs.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In malaria-infected RBCs, the presence of Hb C may inhibit actin polymerization and the production of Maurer's clefts, both of which are necessary for directing parasite-encoded proteins to the surface of infected RBCs [
         <a href="#rid158">
          158
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Further studies have extended these findings and shown that the kinetics of protein trafficking from the parasite to different host cell compartments is delayed, slower, and less effective in parasitized Hb AS and Hb AC erythrocytes [
         <a href="#rid205">
          205
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These data strongly suggest that sequestration of Hb C-containing erythrocytes would be diminished compared with Hb AA-infected RBCs and thus represent a potent mechanism of protection.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Hemoglobin SC disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is likely that individuals with Hb SC disease have significant resistance to malaria.
        </p>
        <p>
         In culture, oxygenated Hb SC cells are indistinguishable from Hb AA cells as a host for Plasmodia. However, the parasite rapidly dies when Hb SC cells are partially deoxygenated [
         <a href="#rid206">
          206
         </a>
         ]. Why this occurs is unclear.
        </p>
        <p>
         Possible mechanisms whereby patients with Hb SC disease might be protected against malaria include [
         <a href="#rid207">
          207
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lowering of the intraerythrocyte pH by parasite metabolism, inducing more deoxy Hb S polymerization in a red cell with high mean corpuscular hemoglobin concentration (MCHC) due to the presence of Hb C.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased crystallization of Hb C induced by the presence of Hb S, creating an inadequate substrate for the parasite's proteases.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Thalassemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both alpha thalassemia and, to a lesser degree, beta thalassemia, are protective against malarial infection, although fewer studies support the selective advantage of thalassemia compared with some other RBC polymorphisms.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiologic evidence
         </strong>
         –
         <strong>
         </strong>
         The initial evidence supporting malaria protection by alpha and beta thalassemia was derived from population genetic studies. Overall, gene frequencies &gt;0.10 are the norm in populations living in tropical climates, whereas frequencies are somewhat lower in the subtropics and rare in the temperate zones.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alpha thalassemia epidemiology
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         While both sickle cell trait and alpha thalassemia offer protection against malaria, this protective effect is lost when alpha thalassemia and the sickle cell variant are coinherited. This phenomenon could explain the failure of alpha thalassemia to reach fixation in any population in sub-Saharan Africa [
         <a href="#rid150">
          150
         </a>
         ]; it could also explain why the sickle cell variant is uncommon in the Mediterranean, where alpha thalassemia is common [
         <a href="#rid208">
          208
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Isolated examples of extreme frequencies have been described in particular groups, particularly in certain tribes in India and Nepal [
         <a href="#rid209">
          209-212
         </a>
         ]. In the Tharu people of Nepal, the alpha thalassemia gene frequency reaches 0.78 [
         <a href="#rid213">
          213
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Dramatic data from communities throughout Melanesia showed a gradient in the alpha thalassemia haplotype frequency both from north to south and with increasing altitude, each of which are paralleled by a gradient in the historical incidence of malaria [
         <a href="#rid214">
          214,215
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A case control study from Africa found lower rates of malaria in individuals who were heterozygous for alpha thalassemia but not in those who were homozygous [
         <a href="#rid216">
          216
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         There is epidemiologic evidence for protection from malaria by alpha thalassemia trait. In a study from the South Pacific and two studies from Africa, the relative risk of severe malaria was significantly reduced in carriers of alpha thalassemia trait [
         <a href="#rid150">
          150,216,217
         </a>
         ]. In Papua New Guinea, severe malaria was less common in individuals homozygous for an alpha thalassemia variant compared with controls without alpha thalassemia (OR 0.40, 95% CI 0.22-0.74) and in individuals heterozygous for an alpha thalassemia variant (OR 0.66, 95% CI 0.37-1.20) [
         <a href="#rid217">
          217
         </a>
         ]. The risk of hospital admission with infections other than malaria was reduced in children who were homozygous for alpha thalassemia variants (OR 0.36, 95% CI 0.22-0.60) and children who were heterozygous (OR 0.63, 95% CI 0.38-1.07) [
         <a href="#rid217">
          217
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Ghanaian children with alpha thalassemia were protected from severe malaria; heterozygous alpha thalassemia showed protection from severe malaria (OR 0.74, 95% CI 0.56-0.98) [
         <a href="#rid216">
          216
         </a>
         ]. In Kenya, alpha thalassemia also conferred protection from severe malaria (adjusted OR 0.73, 95% CI 0.57-0.94 for heterozygous alpha thalassemia and OR 0.57, 95% CI 0.40-0.81 for homozygous alpha thalassemia) [
         <a href="#rid218">
          218
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A 2006 study from Kenya showed that severe malarial anemia was reduced in children heterozygous or homozygous for alpha thalassemia compared with Hb AA controls (IRR 0.33, 95% CI 0.15-0.73) [
         <a href="#rid219">
          219
         </a>
         ]; these findings were confirmed in a larger study [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Beta thalassemia epidemiology
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a population survey in northern Liberia, there was an increasing frequency of beta thalassemia trait with increasing age, suggesting that carriers had increased survival [
         <a href="#rid142">
          142
         </a>
         ]. Using a parasite density of ≥1 x 10
         <sup>
          9
         </sup>
         /L to indicate a potentially lethal infection, the relative risk was 0.45 in children between the ages of one and four with beta thalassemia trait when compared with those without thalassemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a series of classic studies conducted in the 1960s, a gradient (also called a cline) in the population frequencies of beta thalassemia in Sardinia correlated with altitude [
         <a href="#rid220">
          220
         </a>
         ]. Although malaria was no longer endemic in Sardinia, historically, the incidence of malaria was known to have correlated closely with altitude. The favored hypothesis was that the cline represented selection for the thalassemic beta globin gene under pressure from malaria. The gene frequency for beta thalassemia followed a similar correlation with altitude in Papua New Guinea [
         <a href="#rid221">
          221
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanisms of protection
         </strong>
         – Enhanced phagocytosis of ring-parasitized RBCs may represent the common mechanism for malaria protection in nonimmune individuals with beta globin variants, while individuals with alpha thalassemia trait are likely protected by a different mechanism. Increased Hb F may also be protective in individuals with thalassemia, which is associated with a delayed postnatal switch from Hb F to Hb A.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oxidant injury
         </strong>
         – Parasitized RBCs are under substantial oxidant challenge [
         <a href="#rid222">
          222
         </a>
         ]. It has been proposed that oxidant injury is a prominent factor in parasitized alpha and beta thalassemic RBCs and contributes to the protection against severe malarial infection, an effect that may be enhanced by the release of superoxide anions by effector T cells upon binding to the infected RBCs [
         <a href="#rid223">
          223,224
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In addition, the RBC membrane in thalassemic cells undergoes oxidative damage initiated by the binding of excess globin chains, mostly in the form of hemichromes. The combination of intrinsic thalassemic injury and the effect of malarial infection produces an RBC with reduced viability. These changes permit the preferential destruction and removal of thalassemic parasitized RBCs. (See
         <a class="medical medical_review" href="/z/d/html/7090.html" rel="external">
          "Pathophysiology of thalassemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Reduced intracellular growth
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         It is likely that thalassemic RBCs have reduced intraerythrocytic multiplication of
         <em>
          P. falciparum
         </em>
         , potentially delaying the development of life-threatening parasite densities [
         <a href="#rid225">
          225
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Parasite growth impairment is less prominent in cells from individuals who are heterozygous for beta thalassemia than individuals who are heterozygous for alpha thalassemia or who have other thalassemia syndromes (Hb H/Constant Spring or beta thalassemia/Hb E) [
         <a href="#rid226">
          226,227
         </a>
         ]. The mechanisms involved in diminished parasite growth in beta thalassemic cells are not well understood. Oxidant injury may promote the preferential removal of parasitized thalassemic red cells, and persistence of Hb F may contribute in some patients [
         <a href="#rid228">
          228,229
         </a>
         ]. (See
         <a class="local">
          'Fetal hemoglobin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Beta thalassemic mice have lower and delayed peak parasitemia after infection with
         <em>
          P. chabaudi adami
         </em>
         , which has no preference for immature red cells, but not with
         <em>
          P. berghei
         </em>
         , which preferentially invades reticulocytes [
         <a href="#rid230">
          230
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In addition to reduced parasite growth, beta thalassemic RBCs infected with
         <em>
          P. falciparum
         </em>
         show marked reductions in cytoadherence and rosette formation [
         <a href="#rid93">
          93
         </a>
         ]. Infected thalassemic RBCs have decreased expression of surface targeted parasite antigens that mediate these properties.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Malaria-infected RBCs from people with beta thalassemia trait are susceptible to enhanced phagocytosis of ring forms of the parasite. Membrane-bound hemichromes, autologous IgG and complement C3c fragments, aggregated band 3, and phagocytosis by human monocytes were increased in ring forms of the parasite developing in beta thalassemia trait erythrocytes compared with control infected erythrocytes [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Alpha thalassemia-specific mechanisms
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         While there is evidence for reduced parasite growth in individuals who are heterozygous for alpha thalassemia or who have other thalassemia syndromes, some epidemiological and clinical studies suggest that alpha thalassemia may confer protection by additional mechanisms. These studies do not necessarily preclude similar mechanisms in the beta thalassemia syndrome, but equivalent studies have not been performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The protection against severe malaria associated with alpha thalassemia may be mediated in part by increased susceptibility to infection with the nonlethal
         <em>
          P. vivax
         </em>
         , particularly in young children, thereby inducing limited cross-species protection against subsequent severe
         <em>
          P. falciparum
         </em>
         infection [
         <a href="#rid227">
          227,231,232
         </a>
         ]. This possibility was illustrated in a study of the epidemiology of malaria in Vanuatu in the northeast Pacific [
         <a href="#rid232">
          232
         </a>
         ]. The prevalence of uncomplicated malaria (
         <em>
          P. falciparum
         </em>
         and
         <em>
          P. vivax
         </em>
         ) and of splenomegaly (commonly associated with malaria infection) was increased among children &lt;5 years old with alpha thalassemia; this was not seen in older children.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Alpha thalassemia is associated with reduced expression of red cell complement receptor 1 (CR1), responsible for red cell rosetting of infected and noninfected red cells. Low CR1 expression on reticulocytes reduces the ability of
         <em>
          P. vivax
         </em>
         to invade [
         <a href="#rid106">
          106
         </a>
         ]. (See
         <a class="local">
          'Knops blood group (complement receptor 1)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Infected RBCs from people with alpha thalassemia appear to have reduced expression of the variant antigen Pf-EMP-1 and subsequently reduced adherence of infected RBCs to microvascular endothelial cells (MVECs) and monocytes in vitro [
         <a href="#rid233">
          233
         </a>
         ]. Such a mechanism may reduce sequestration and the progression to severe disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Some of the protective effect of homozygous alpha thalassemia on severe anemia may be explained by the increased erythrocyte count and microcytosis, allowing a greater reduction in erythrocyte count than children of normal genotype during malaria infection before the hemoglobin level falls to cause severe anemia (eg, total hemoglobin concentration &lt;5 g/dL) [
         <a href="#rid234">
          234,235
         </a>
         ]. This is likely to apply to beta thalassemia as well, although similar studies have not been performed with beta thalassemic RBCs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interaction with haptoglobin genotypes
         </strong>
         – It is unknown if variation in genotype for
         <em>
          HP
         </em>
         , which encodes haptoglobin, alters the risk for severe malaria in individuals with thalassemia, with studies producing conflicting results.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One study uncovered a significant epistatic interaction between alpha thalassemia a
         <em>
          nd
         </em>
         <em>
          HP
         </em>
         genotype that may explain why studies that do not examine both genotypes could give conflicting results. Whereas Hp2-1, inherited in combination with al
         <sup>
          p
         </sup>
         ha
         <sup>
          +
         </sup>
         thalassemia, offered significant (37 percent) protection against severe malaria (37 percent), such protection was considerably reduced (13 percent protection) when inherited in combination with a normal alpha globin genotype [
         <a href="#rid236">
          236
         </a>
         ]. Moreover, in those with alpha thalassemia, protection was lost altogether when inherited in combination with Hp2-2. The data require confirmation in other groups and/or further mechanistic studies before firm conclusions can be drawn.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2448882133">
         <span class="h2">
          Hemoglobin E
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hb E is a beta globin (
         <em>
          HBB
         </em>
         ) variant that reduces beta globin expression (a beta thalassemic phenotype). It is due to a point mutation that substitutes lysine for glutamic acid at amino acid 26 of the beta globin chain (Glu26Lys). (See
         <a class="medical medical_review" href="/z/d/html/7127.html" rel="external">
          "Hemoglobin variants including Hb C, Hb D, and Hb E", section on 'Hb E'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiologic evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is no direct evidence for the protective effect of Hb E in malaria, but early epidemiological studies suggested a connection [
         <a href="#rid237">
          237
         </a>
         ]. The pattern of linkage disequilibrium surrounding the beta globin locus in Thailand suggests a single origin of Hb E arising between 1200 to 4400 years ago and a rapid increase in allelic frequency [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hb E is the most frequent hemoglobin structural variant in Southeast Asia [
         <a href="#rid237">
          237
         </a>
         ]. The highest frequency of this gene is observed in the "Hb E triangle" where the frontiers of Cambodia, Laos, and Thailand converge.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the central region of Indochina, genetic changes in RBC proteins including Hb E, thalassemia, and glucose-6-phosphate dehydrogenase (G6PD) are so common that only approximately 15 percent of the population has RBCs that lack a malaria-protective variant [
         <a href="#rid238">
          238
         </a>
         ]. (See
         <a class="local">
          'G6PD deficiency'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In one study, individuals with Hb AE and EE had significantly higher levels of antimalarial antibodies than individuals with Hb AA from the same geographic areas [
         <a href="#rid239">
          239
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanistic evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Initial in vitro studies of the relationship between
         <em>
          P. falciparum
         </em>
         and Hb E-containing cells demonstrated a moderate decrease in growth of
         <em>
          P. falciparum
         </em>
         in homozygous Hb E RBCs but not Hb E trait RBCs [
         <a href="#rid240">
          240
         </a>
         ]. A subsequent report showed diminished growth of parasites in both Hb E trait and Hb E disease cells that was most pronounced as the concentration of Hb E increased; this effect was maximal at 20 percent oxygen and decreased but present at 5 percent oxygen [
         <a href="#rid239">
          239
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Additional studies suggest that RBCs from individuals with Hb E trait are relatively resistant to invasion by
         <em>
          P. falciparum
         </em>
         , which may reduce parasite burden during infection [
         <a href="#rid241">
          241
         </a>
         ]. In addition, Hb E is somewhat unstable and is capable of generating free radicals and inducing oxidative damage to the RBC membrane [
         <a href="#rid242">
          242
         </a>
         ]. The oxidant activity of Hb E may explain the greater rate of monocyte phagocytosis of parasitized RBCs from individuals homozygous for Hb E and heterozygous (Hb E trait) relative to individuals with Hb AA [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3820283910">
         <span class="h2">
          Fetal hemoglobin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fetal hemoglobin (Hb F; a tetramer of alpha globin and gamma globin [alpha2gamma2]) is the main hemoglobin in fetal RBCs. At birth, it accounts for approximately 60 percent of total hemoglobin; by six months of age, it accounts for &lt;1 percent of total hemoglobin. (See
         <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">
          "Fetal hemoglobin (Hb F) in health and disease", section on 'Hemoglobin switching and downregulation of Hb F expression'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90749.html" rel="external">
          "Fetal hemoglobin (Hb F) in health and disease", section on 'Hereditary persistence of fetal hemoglobin (HPFH)'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiologic evidence
         </strong>
         – There is a correlation between reduced risk of malaria and increased Hb F levels in early infancy, but there is not strong epidemiologic evidence that Hb F is protective.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Resistance to malaria during the first six months of life can be explained by two mechanisms: increased malaria invasion of Hb F-containing cells, resulting in fewer parasites available for invasion of the Hb A-containing cells; and slowed growth within the Hb F cells [
         <a href="#rid229">
          229
         </a>
         ]. Protection during the first six months of life is critical, since humoral and cellular defenses are not yet effective, although transferred maternal antibodies may confer relative protection from malaria in infancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanistic evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Some studies have found that growth of
         <em>
          P. falciparum
         </em>
         is diminished in red cells containing fetal hemoglobin (Hb F), even though parasite invasion may be increased in umbilical cord red cells, which have a high concentration of Hb F [
         <a href="#rid228">
          228,229
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Reduced parasite growth can be demonstrated in cord blood cells containing a majority of Hb F, F cells from infants (which contain about 20 percent Hb F), and RBCs from adults who are homozygous for hereditary persistence of fetal hemoglobin (HPFH), which contain nearly 100 percent Hb F [
         <a href="#rid229">
          229
         </a>
         ]. However, other groups have not found such reduced parasite growth in cells with more Hb F [
         <a href="#rid243">
          243
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Initial studies suggest that the decrease in parasite growth associated with the presence of Hb F may be mediated by an increase in intraerythrocytic oxidative stress [
         <a href="#rid244">
          244
         </a>
         ]. This mechanism was studied directly in transgenic mice with 40 to 60 percent Hb F [
         <a href="#rid245">
          245
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In mice infected with
         <em>
          P. yoelii
         </em>
         17XL, which produces a syndrome resembling cerebral malaria caused by
         <em>
          P. falciparum
         </em>
         in humans, light microscopy revealed that intraerythrocytic parasites developed more slowly in Hb F-containing erythrocytes [
         <a href="#rid246">
          246
         </a>
         ]. Hb F was digested only one-half as well as Hb A by malarial hemoglobinases (recombinant plasmepsin II), which could explain the slowing of parasite growth.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3813195120">
         <span class="h1">
          RBC ENZYME DEFICIENCIES
         </span>
        </p>
        <p class="headingAnchor" id="H437643706">
         <span class="h2">
          G6PD deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme that protects cells against oxidant damage. G6PD deficiency is the most common inherited RBC enzyme abnormality, affecting 400 million people worldwide. G6PD deficiency is an X-linked disorder, with males more likely to be affected than females. (See
         <a class="medical medical_review" href="/z/d/html/7109.html" rel="external">
          "Genetics and pathophysiology of glucose-6-phosphate dehydrogenase (G6PD) deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiologic evidence
         </strong>
         –
         <strong>
         </strong>
         The global pattern of G6PD deficiency parallels areas where malaria was once endemic, including sub-Saharan Africa, South America, South Asia, India, and the Mediterranean region  (
         <a class="graphic graphic_figure graphicRef129472" href="/z/d/graphic/129472.html" rel="external">
          figure 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanistic evidence
         </strong>
         – Enhanced phagocytosis of ring or the early intraerythrocytic form of the parasite may be an explanation for protection in G6PD deficiency [
         <a href="#rid156">
          156
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2420980177">
         <span class="h2">
          Pyruvate kinase deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pyruvate kinase (PK) catalyzes the final step in the glycolytic pathway, involving transfer of a phosphate group from phosphoenolpyruvate to adenosine diphosphate. PK deficiency causes hemolytic anemia. (See
         <a class="medical medical_review" href="/z/d/html/7129.html" rel="external">
          "Pyruvate kinase deficiency"
         </a>
         .)
        </p>
        <p>
         PK deficiency is protective against malaria in mouse models, but protection has not been demonstrated in human populations. PK-deficient mice are protected from malaria [
         <a href="#rid247">
          247
         </a>
         ]. Furthermore,
         <em>
          P. falciparum
         </em>
         parasites showed reduced growth in RBCs from individuals with PK deficiency relative to control RBCs [
         <a href="#rid248">
          248
         </a>
         ].
        </p>
        <p>
         Some genetic variants that cause PK deficiency have reached polymorphic frequencies in malaria-endemic areas, although these variants have not been demonstrated to confer resistance to severe malaria [
         <a href="#rid249">
          249
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14230701">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanistic insights
         </strong>
         – Malarial invasion of the red blood cell (RBC) is a complex multistep process. Evolutionary pressure that began thousands of years ago has selected for gene variants that protect against malaria by blocking one or more of these steps; the geographic distribution of these gene variants parallels the regions where
         <em>
          Plasmodium falciparum
         </em>
         or
         <em>
          P. vivax
         </em>
         is or was endemic. (See
         <a class="local">
          'Evolutionary selection pressure from malaria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Merozoite entry into the RBC via surface proteins that act as malaria ligands
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intracellular parasite growth
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lysis of the RBC as the parasite matures
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immune response affecting sequestration and clearance of infected RBCs
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Parasite invasion
         </strong>
         – Host variants of RBC surface proteins can reduce parasite invasion. Many of these surface proteins are blood group antigens. (See
         <a class="local">
          'RBC surface proteins'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Duffy-null RBCs are protected against
         <em>
          P. vivax
         </em>
         . (See
         <a class="local">
          'Duffy blood group system'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Variation in the ABO, MNS, Gerbich, Knops, and Ok blood group systems may confer protection by reducing invasion and/or parasite growth. (See
         <a class="local">
          'ABO blood group system'
         </a>
         above and
         <a class="local">
          'MNS blood group system (glycophorins A and B)'
         </a>
         above and
         <a class="local">
          'Gerbich blood group (glycophorin C)'
         </a>
         above and
         <a class="local">
          'Knops blood group (complement receptor 1)'
         </a>
         above and
         <a class="local">
          'Ok blood group antigen (basigin)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Variants affecting RBC membrane channels ATP2B4, ferroportin, and Piezo1 may be protective. (See
         <a class="local">
          'Membrane channels'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Variants affecting cytoskeletal proteins that may be protective include Southeast Asian ovalocytosis (SAO), hereditary elliptocytosis, and hereditary spherocytosis. (See
         <a class="local">
          'RBC cytoskeletal changes'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7087.html" rel="external">
          "Hereditary elliptocytosis and related disorders"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7079.html" rel="external">
          "Hereditary spherocytosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Parasite growth
         </strong>
         – Variant hemoglobins (especially the sickle cell variant and Hb C  (
         <a class="graphic graphic_figure graphicRef131447" href="/z/d/graphic/131447.html" rel="external">
          figure 2
         </a>
         )), thalassemias, and increased fetal hemoglobin (Hb F) have evolved in malaria-endemic areas. (See
         <a class="local">
          'Hemoglobinopathies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hemoglobinopathies are protective in the heterozygous state, and heterozygosity is clinically well tolerated, but homozygosity or compound heterozygosity can cause serious disease. (See
         <a class="medical medical_review" href="/z/d/html/7145.html" rel="external">
          "Sickle cell trait"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7127.html" rel="external">
          "Hemoglobin variants including Hb C, Hb D, and Hb E"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7116.html" rel="external">
          "Diagnosis of thalassemia (adults and children)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Glucose-6-phosphate dehydrogenase (G6PD) protects RBCs against oxidant injury. G6PD deficiency is seen throughout malaria endemic regions of the world  (
         <a class="graphic graphic_figure graphicRef129472" href="/z/d/graphic/129472.html" rel="external">
          figure 3
         </a>
         ). The mechanism by which G6PD deficiency provides protection against malaria appears to be an increase in oxidant stress in infected RBCs with enhanced phagocytosis of ring or early intraerythrocytic forms of the parasite. (See
         <a class="local">
          'G6PD deficiency'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7109.html" rel="external">
          "Genetics and pathophysiology of glucose-6-phosphate dehydrogenase (G6PD) deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pyruvate kinase (PK) deficiency is protective in experimental murine malaria, but protection has not been demonstrated in human populations. (See
         <a class="medical medical_review" href="/z/d/html/7129.html" rel="external">
          "Pyruvate kinase deficiency", section on 'Possible protection from malaria'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3165960564">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wiesenfeld SL. Sickle-cell trait in human biological and cultural evolution. Development of agriculture causing increased malaria is bound to gene-pool changes causing malaria reduction. Science 1967; 157:1134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camus D, Hadley TJ. A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Science 1985; 230:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohashi J, Naka I, Patarapotikul J, et al. Extended linkage disequilibrium surrounding the hemoglobin E variant due to malarial selection. Am J Hum Genet 2004; 74:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartl DL. The origin of malaria: mixed messages from genetic diversity. Nat Rev Microbiol 2004; 2:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loy DE, Liu W, Li Y, et al. Out of Africa: origins and evolution of the human malaria parasites Plasmodium falciparum and Plasmodium vivax. Int J Parasitol 2017; 47:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu W, Li Y, Learn GH, et al. Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature 2010; 467:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laval G, Peyrégne S, Zidane N, et al. Recent Adaptive Acquisition by African Rainforest Hunter-Gatherers of the Late Pleistocene Sickle-Cell Mutation Suggests Past Differences in Malaria Exposure. Am J Hum Genet 2019; 104:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paquette AM, Harahap A, Laosombat V, et al. The evolutionary origins of Southeast Asian Ovalocytosis. Infect Genet Evol 2015; 34:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shriner D, Rotimi CN. Whole-Genome-Sequence-Based Haplotypes Reveal Single Origin of the Sickle Allele during the Holocene Wet Phase. Am J Hum Genet 2018; 102:547.
          </a>
         </li>
         <li class="breakAll">
          Klebs E, Tommasi-Crudeli C. On the Nature of Malaria, Translated by Drummond E, Reale Academia Dei Lincei, Rome 1888. https://wellcomecollection.org/works/rjpk7h9e/items (Accessed on March 10, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haldane JB. Disease and Evolution. La Ricerce Scientifica 1949; 19:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ALLISON AC. Protection afforded by sickle-cell trait against subtertian malareal infection. Br Med J 1954; 1:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           May J, Evans JA, Timmann C, et al. Hemoglobin variants and disease manifestations in severe falciparum malaria. JAMA 2007; 297:2220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aidoo M, Terlouw DJ, Kolczak MS, et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 2002; 359:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flint J, Harding RM, Clegg JB, Boyce AJ. Why are some genetic diseases common? Distinguishing selection from other processes by molecular analysis of globin gene variants. Hum Genet 1993; 91:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackinnon MJ, Gunawardena DM, Rajakaruna J, et al. Quantifying genetic and nongenetic contributions to malarial infection in a Sri Lankan population. Proc Natl Acad Sci U S A 2000; 97:12661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackinnon MJ, Mwangi TW, Snow RW, et al. Heritability of malaria in Africa. PLoS Med 2005; 2:e340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kariuki SN, Williams TN. Human genetics and malaria resistance. Hum Genet 2020; 139:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller LH, Aikawa M, Johnson JG, Shiroishi T. Interaction between cytochalasin B-treated malarial parasites and erythrocytes. Attachment and junction formation. J Exp Med 1979; 149:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns AL, Dans MG, Balbin JM, et al. Targeting malaria parasite invasion of red blood cells as an antimalarial strategy. FEMS Microbiol Rev 2019; 43:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sim BK, Chitnis CE, Wasniowska K, et al. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 1994; 264:1941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang L, Duriseti S, Sun P, Miller LH. Molecular basis of binding of the Plasmodium falciparum receptor BAEBL to erythrocyte receptor glycophorin C. Mol Biochem Parasitol 2009; 168:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaskiewicz E, Jodłowska M, Kaczmarek R, Zerka A. Erythrocyte glycophorins as receptors for Plasmodium merozoites. Parasit Vectors 2019; 12:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molina-Franky J, Patarroyo ME, Kalkum M, Patarroyo MA. The Cellular and Molecular Interaction Between Erythrocytes and Plasmodium falciparum Merozoites. Front Cell Infect Microbiol 2022; 12:816574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chitnis CE, Miller LH. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 1994; 180:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams JH, Sim BK, Dolan SA, et al. A family of erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci U S A 1992; 89:7085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ndila CM, Uyoga S, Macharia AW, et al. Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study. Lancet Haematol 2018; 5:e333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bunyaratvej A, Butthep P, Yuthavong Y, et al. Increased phagocytosis of Plasmodium falciparum-infected erythrocytes with haemoglobin E by peripheral blood monocytes. Acta Haematol 1986; 76:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuthavong Y, Butthep P, Bunyaratvej A, et al. Impaired parasite growth and increased susceptibility to phagocytosis of Plasmodium falciparum infected alpha-thalassemia or hemoglobin Constant Spring red blood cells. Am J Clin Pathol 1988; 89:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayi K, Turrini F, Piga A, Arese P. Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait. Blood 2004; 104:3364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shear HL, Roth EF Jr, Fabry ME, et al. Transgenic mice expressing human sickle hemoglobin are partially resistant to rodent malaria. Blood 1993; 81:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill AV, Allsopp CE, Kwiatkowski D, et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991; 352:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill AV, Elvin J, Willis AC, et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992; 360:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nash GB, O'Brien E, Gordon-Smith EC, Dormandy JA. Abnormalities in the mechanical properties of red blood cells caused by Plasmodium falciparum. Blood 1989; 74:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paulitschke M, Nash GB. Membrane rigidity of red blood cells parasitized by different strains of Plasmodium falciparum. J Lab Clin Med 1993; 122:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uyoga S, Watson JA, Wanjiku P, et al. The impact of malaria-protective red blood cell polymorphisms on parasite biomass in children with severe Plasmodium falciparum malaria. Nat Commun 2022; 13:3307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhuri A, Polyakova J, Zbrzezna V, Pogo AO. The coding sequence of Duffy blood group gene in humans and simians: restriction fragment length polymorphism, antibody and malarial parasite specificities, and expression in nonerythroid tissues in Duffy-negative individuals. Blood 1995; 85:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadley TJ, David PH, McGinniss MH, Miller LH. Identification of an erythrocyte component carrying the Duffy blood group Fya antigen. Science 1984; 223:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhuri A, Zbrzezna V, Johnson C, et al. Purification and characterization of an erythrocyte membrane protein complex carrying Duffy blood group antigenicity. Possible receptor for Plasmodium vivax and Plasmodium knowlesi malaria parasite. J Biol Chem 1989; 264:13770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tournamille C, Colin Y, Cartron JP, Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet 1995; 10:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welch SG, McGregor IA, Williams K. The Duffy blood group and malaria prevalence in Gambian West Africans. Trans R Soc Trop Med Hyg 1977; 71:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandler SG, Kravitz C, Sharon R, et al. The Duffy blood group system in Israeli Jews and Arabs. Vox Sang 1979; 37:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimmerman PA, Woolley I, Masinde GL, et al. Emergence of FY*A(null) in a Plasmodium vivax-endemic region of Papua New Guinea. Proc Natl Acad Sci U S A 1999; 96:13973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilairatana P, Masangkay FR, Kotepui KU, et al. Prevalence and risk of Plasmodium vivax infection among Duffy-negative individuals: a systematic review and meta-analysis. Sci Rep 2022; 12:3998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King CL, Adams JH, Xianli J, et al. Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria. Proc Natl Acad Sci U S A 2011; 108:20113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           YOUNG MD, EYLES DE, BURGESS RW, JEFFERY GM. Experimental testing of the immunity of Negroes to Plasmodium vivax. J Parasitol 1955; 41:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 1976; 295:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller LH, Mason SJ, Dvorak JA, et al. Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science 1975; 189:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wertheimer SP, Barnwell JW. Plasmodium vivax interaction with the human Duffy blood group glycoprotein: identification of a parasite receptor-like protein. Exp Parasitol 1989; 69:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnwell JW, Nichols ME, Rubinstein P. In vitro evaluation of the role of the Duffy blood group in erythrocyte invasion by Plasmodium vivax. J Exp Med 1989; 169:1795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horuk R, Chitnis CE, Darbonne WC, et al. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 1993; 261:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chitnis CE, Chaudhuri A, Horuk R, et al. The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes. J Exp Med 1996; 184:1531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMorran BJ, Wieczorski L, Drysdale KE, et al. Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum. Science 2012; 338:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuboi T, Kappe SH, al-Yaman F, et al. Natural variation within the principal adhesion domain of the Plasmodium vivax duffy binding protein. Infect Immun 1994; 62:5581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranjan A, Chitnis CE. Mapping regions containing binding residues within functional domains of Plasmodium vivax and Plasmodium knowlesi erythrocyte-binding proteins. Proc Natl Acad Sci U S A 1999; 96:14067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batchelor JD, Malpede BM, Omattage NS, et al. Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC. PLoS Pathog 2014; 10:e1003869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh S, Pandey K, Chattopadhayay R, et al. Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax duffy-binding protein. J Biol Chem 2001; 276:17111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rawlinson TA, Barber NM, Mohring F, et al. Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody. Nat Microbiol 2019; 4:1497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Payne RO, Silk SE, Elias SC, et al. Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. JCI Insight 2017; 2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George MT, Schloegel JL, Ntumngia FB, et al. Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain. mSphere 2019; 4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ntumngia FB, Schloegel J, McHenry AM, et al. Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II. Vaccine 2013; 31:4382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hou MM, Barrett JR, Themistocleous Y, et al. Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection. Sci Transl Med 2023; 15:eadf1782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sisquella X, Nebl T, Thompson JK, et al. Plasmodium falciparum ligand binding to erythrocytes induce alterations in deformability essential for invasion. Elife 2017; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller LH, Haynes JD, McAuliffe FM, et al. Evidence for differences in erythrocyte surface receptors for the malarial parasites, Plasmodium falciparum and Plasmodium knowlesi. J Exp Med 1977; 146:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perkins M. Inhibitory effects of erythrocyte membrane proteins on the in vitro invasion of the human malarial parasite (Plasmodium falciparum) into its host cell. J Cell Biol 1981; 90:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breuer WV, Kahane I, Baruch D, et al. Role of internal domains of glycophorin in Plasmodium falciparum invasion of human erythrocytes. Infect Immun 1983; 42:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman MJ, Blankenberg T, Sensabaugh G, Tenforde TS. Recognition and invasion of human erythrocytes by malarial parasites: contribution of sialoglycoproteins to attachment and host specificity. J Cell Biol 1984; 98:1672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasvol G, Jungery M, Weatherall DJ, et al. Glycophorin as a possible receptor for Plasmodium falciparum. Lancet 1982; 2:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasvol G, Wainscoat JS, Weatherall DJ. Erythrocytes deficiency in glycophorin resist invasion by the malarial parasite Plasmodium falciparum. Nature 1982; 297:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cartron JP, Prou O, Luilier M, Soulier JP. Susceptibility to invasion by Plasmodium falciparum of some human erythrocytes carrying rare blood group antigens. Br J Haematol 1983; 55:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mourant AE. Genetical polymorphisms and the incidence of disease. Proc R Soc Med 1968; 61:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dankwa S, Chaand M, Kanjee U, et al. Genetic Evidence for Erythrocyte Receptor Glycophorin B Expression Levels Defining a Dominant Plasmodium falciparum Invasion Pathway into Human Erythrocytes. Infect Immun 2017; 85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayer DC, Cofie J, Jiang L, et al. Glycophorin B is the erythrocyte receptor of Plasmodium falciparum erythrocyte-binding ligand, EBL-1. Proc Natl Acad Sci U S A 2009; 106:5348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadley TJ, Klotz FW, Pasvol G, et al. Falciparum malaria parasites invade erythrocytes that lack glycophorin A and B (MkMk). Strain differences indicate receptor heterogeneity and two pathways for invasion. J Clin Invest 1987; 80:1190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malaria Genomic Epidemiology Network, Band G, Rockett KA, et al. A novel locus of resistance to severe malaria in a region of ancient balancing selection. Nature 2015; 526:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leffler EM, Band G, Busby GBJ, et al. Resistance to malaria through structural variation of red blood cell invasion receptors. Science 2017; 356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Field SP, Hempelmann E, Mendelow BV, Fleming AF. Glycophorin variants and Plasmodium falciparum: protective effect of the Dantu phenotype in vitro. Hum Genet 1994; 93:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kariuki SN, Marin-Menendez A, Introini V, et al. Red blood cell tension protects against severe malaria in the Dantu blood group. Nature 2020; 585:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maier AG, Duraisingh MT, Reeder JC, et al. Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations. Nat Med 2003; 9:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serjeantson SW. A selective advantage for the Gerbich-negative phenotype in malarious areas of Papua New Guinea. P N G Med J 1989; 32:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel SS, Mehlotra RK, Kastens W, et al. The association of the glycophorin C exon 3 deletion with ovalocytosis and malaria susceptibility in the Wosera, Papua New Guinea. Blood 2001; 98:3489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magowan C, Coppel RL, Lau AO, et al. Role of the Plasmodium falciparum mature-parasite-infected erythrocyte surface antigen (MESA/PfEMP-2) in malarial infection of erythrocytes. Blood 1995; 86:3196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chishti AH, Palek J, Fisher D, et al. Reduced invasion and growth of Plasmodium falciparum into elliptocytic red blood cells with a combined deficiency of protein 4.1, glycophorin C, and p55. Blood 1996; 87:3462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lobo CA, Rodriguez M, Reid M, Lustigman S. Glycophorin C is the receptor for the Plasmodium falciparum erythrocyte binding ligand PfEBP-2 (baebl). Blood 2003; 101:4628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waller KL, Cooke BM, Nunomura W, et al. Mapping the binding domains involved in the interaction between the Plasmodium falciparum knob-associated histidine-rich protein (KAHRP) and the cytoadherence ligand P. falciparum erythrocyte membrane protein 1 (PfEMP1). J Biol Chem 1999; 274:23808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Senczuk AM, Reeder JC, Kosmala MM, Ho M. Plasmodium falciparum erythrocyte membrane protein 1 functions as a ligand for P-selectin. Blood 2001; 98:3132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fry AE, Griffiths MJ, Auburn S, et al. Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria. Hum Mol Genet 2008; 17:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cserti-Gazdewich CM, Dhabangi A, Musoke C, et al. Cytoadherence in paediatric malaria: ABO blood group, CD36, and ICAM1 expression and severe Plasmodium falciparum infection. Br J Haematol 2012; 159:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer PR, Boone P. Short report: severe malaria associated with blood group. Am J Trop Med Hyg 1998; 58:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lell B, May J, Schmidt-Ott RJ, et al. The role of red blood cell polymorphisms in resistance and susceptibility to malaria. Clin Infect Dis 1999; 28:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson J, Wahlgren M. Plasmodium falciparum erythrocyte rosetting is mediated by promiscuous lectin-like interactions. J Exp Med 1992; 176:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barragan A, Kremsner PG, Wahlgren M, Carlson J. Blood group A antigen is a coreceptor in Plasmodium falciparum rosetting. Infect Immun 2000; 68:2971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udomsangpetch R, Sueblinvong T, Pattanapanyasat K, et al. Alteration in cytoadherence and rosetting of Plasmodium falciparum-infected thalassemic red blood cells. Blood 1993; 82:3752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowe A, Obeiro J, Newbold CI, Marsh K. Plasmodium falciparum rosetting is associated with malaria severity in Kenya. Infect Immun 1995; 63:2323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chotivanich KT, Udomsangpetch R, Pipitaporn B, et al. Rosetting characteristics of uninfected erythrocytes from healthy individuals and malaria patients. Ann Trop Med Parasitol 1998; 92:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowe JA, Handel IG, Thera MA, et al. Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A 2007; 104:17471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolofsky KT, Ayi K, Branch DR, et al. ABO blood groups influence macrophage-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes. PLoS Pathog 2012; 8:e1002942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen M, Hurtado-Ziola N, Varki A. ABO blood group glycans modulate sialic acid recognition on erythrocytes. Blood 2009; 114:3668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jajosky RP, Jajosky AN, Jajosky PG. ABO blood group should be considered and reported when red blood cell exchange transfusion is used to treat Plasmodiumfalciparum Malaria patients. Transfus Clin Biol 2020; 27:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moulds JM, Zimmerman PA, Doumbo OK, et al. Molecular identification of Knops blood group polymorphisms found in long homologous region D of complement receptor 1. Blood 2001; 97:2879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thathy V, Moulds JM, Guyah B, et al. Complement receptor 1 polymorphisms associated with resistance to severe malaria in Kenya. Malar J 2005; 4:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tettey R, Ayeh-Kumi P, Tettey P, et al. Severity of malaria in relation to a complement receptor 1 polymorphism: a case-control study. Pathog Glob Health 2015; 109:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Opi DH, Swann O, Macharia A, et al. Two complement receptor one alleles have opposing associations with cerebral malaria and interact with α+thalassaemia. Elife 2018; 7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansson HH, Kurtzhals JA, Goka BQ, et al. Human genetic polymorphisms in the Knops blood group are not associated with a protective advantage against Plasmodium falciparum malaria in Southern Ghana. Malar J 2013; 12:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spadafora C, Awandare GA, Kopydlowski KM, et al. Complement receptor 1 is a sialic acid-independent erythrocyte receptor of Plasmodium falciparum. PLoS Pathog 2010; 6:e1000968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prajapati SK, Borlon C, Rovira-Vallbona E, et al. Complement Receptor 1 availability on red blood cell surface modulates Plasmodium vivax invasion of human reticulocytes. Sci Rep 2019; 9:8943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tham WH, Schmidt CQ, Hauhart RE, et al. Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes. Blood 2011; 118:1923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowe JA, Moulds JM, Newbold CI, Miller LH. P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. Nature 1997; 388:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crosnier C, Bustamante LY, Bartholdson SJ, et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 2011; 480:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong W, Huang R, Menant S, et al. Structure of Plasmodium falciparum Rh5-CyRPA-Ripr invasion complex. Nature 2019; 565:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aniweh Y, Gao X, Hao P, et al. P. falciparum RH5-Basigin interaction induces changes in the cytoskeleton of the host RBC. Cell Microbiol 2017; 19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wanaguru M, Liu W, Hahn BH, et al. RH5-Basigin interaction plays a major role in the host tropism of Plasmodium falciparum. Proc Natl Acad Sci U S A 2013; 110:20735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas AD, Williams AR, Knuepfer E, et al. Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5. J Immunol 2014; 192:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zenonos ZA, Dummler SK, Müller-Sienerth N, et al. Basigin is a druggable target for host-oriented antimalarial interventions. J Exp Med 2015; 212:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timmann C, Thye T, Vens M, et al. Genome-wide association study indicates two novel resistance loci for severe malaria. Nature 2012; 489:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lessard S, Gatof ES, Beaudoin M, et al. An erythroid-specific ATP2B4 enhancer mediates red blood cell hydration and malaria susceptibility. J Clin Invest 2017; 127:3065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang DL, Wu J, Shah BN, et al. Erythrocytic ferroportin reduces intracellular iron accumulation, hemolysis, and malaria risk. Science 2018; 359:1520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muriuki JM, Mentzer AJ, Band G, et al. The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia. Sci Adv 2019; 5:eaaw0109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiffert T, Lew VL, Ginsburg H, et al. The hydration state of human red blood cells and their susceptibility to invasion by Plasmodium falciparum. Blood 2005; 105:4853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma S, Cahalan S, LaMonte G, et al. Common PIEZO1 Allele in African Populations Causes RBC Dehydration and Attenuates Plasmodium Infection. Cell 2018; 173:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shear HL, Roth EF Jr, Ng C, Nagel RL. Resistance to malaria in ankyrin and spectrin deficient mice. Br J Haematol 1991; 78:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serjeantson S, Bryson K, Amato D, Babona D. Malaria and hereditary ovalocytosis. Hum Genet 1977; 37:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosanas-Urgell A, Lin E, Manning L, et al. Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study. PLoS Med 2012; 9:e1001305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genton B, al-Yaman F, Mgone CS, et al. Ovalocytosis and cerebral malaria. Nature 1995; 378:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell A, Allen SJ, Mgone CS, et al. Red cell morphology and malaria anaemia in children with Southeast-Asian ovalocytosis band 3 in Papua New Guinea. Br J Haematol 1998; 101:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kidson C, Lamont G, Saul A, Nurse GT. Ovalocytic erythrocytes from Melanesians are resistant to invasion by malaria parasites in culture. Proc Natl Acad Sci U S A 1981; 78:5829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadley T, Saul A, Lamont G, et al. Resistance of Melanesian elliptocytes (ovalocytes) to invasion by Plasmodium knowlesi and Plasmodium falciparum malaria parasites in vitro. J Clin Invest 1983; 71:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bunyaratvej A, Butthep P, Kaewkettong P, Yuthavong Y. Malaria protection in hereditary ovalocytosis: relation to red cell deformability, red cell parameters and degree of ovalocytosis. Southeast Asian J Trop Med Public Health 1997; 28 Suppl 3:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller LH, Hudson D, Rener J, et al. A monoclonal antibody to rhesus erythrocyte band 3 inhibits invasion by malaria (Plasmodium knowlesi) merozoites. J Clin Invest 1983; 72:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohandas N, Lie-Injo LE, Friedman M, Mak JW. Rigid membranes of Malayan ovalocytes: a likely genetic barrier against malaria. Blood 1984; 63:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apibal S, Suwannurak R, Bunyaratvej A, et al. Increased ovalocytic red cells and their low parasitemia in malaria infected subjects. J Med Assoc Thai 1989; 72:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagel RL. Red-cell cytoskeletal abnormalities--implications for malaria. N Engl J Med 1990; 323:1558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glele-Kakai C, Garbarz M, Lecomte MC, et al. Epidemiological studies of spectrin mutations related to hereditary elliptocytosis and spectrin polymorphisms in Benin. Br J Haematol 1996; 95:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhermy D, Schrével J, Lecomte MC. Spectrin-based skeleton in red blood cells and malaria. Curr Opin Hematol 2007; 14:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gratzer WB, Dluzewski AR. The red blood cell and malaria parasite invasion. Semin Hematol 1993; 30:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulman S, Roth EF Jr, Cheng B, et al. Growth of Plasmodium falciparum in human erythrocytes containing abnormal membrane proteins. Proc Natl Acad Sci U S A 1990; 87:7339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chishti AH, Maalouf GJ, Marfatia S, et al. Phosphorylation of protein 4.1 in Plasmodium falciparum-infected human red blood cells. Blood 1994; 83:3339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rank G, Sutton R, Marshall V, et al. Novel roles for erythroid Ankyrin-1 revealed through an ENU-induced null mouse mutant. Blood 2009; 113:3352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor SM, Parobek CM, Fairhurst RM. Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BEET EA. Sickle cell disease in the Balovale District of Northern Rhodesia. East Afr Med J 1946; 23:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ALLISON AC. POLYMORPHISM AND NATURAL SELECTION IN HUMAN POPULATIONS. Cold Spring Harb Symp Quant Biol 1964; 29:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willcox M, Björkman A, Brohult J. Falciparum malaria and beta-thalassaemia trait in northern Liberia. Ann Trop Med Parasitol 1983; 77:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming AF, Storey J, Molineaux L, et al. Abnormal haemoglobins in the Sudan savanna of Nigeria. I. Prevalence of haemoglobins and relationships between sickle cell trait, malaria and survival. Ann Trop Med Parasitol 1979; 73:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsh K, Otoo L, Hayes RJ, et al. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg 1989; 83:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jakobsen PH, Riley EM, Allen SJ, et al. Differential antibody response of Gambian donors to soluble Plasmodium falciparum antigens. Trans R Soc Trop Med Hyg 1991; 85:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           do Sambo MR, Penha-Gonçalves C, Trovoada MJ, et al. Quantitative trait locus analysis of parasite density reveals that HbS gene carriage protects severe malaria patients against Plasmodium falciparum hyperparasitaemia. Malar J 2015; 14:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott JA, Berkley JA, Mwangi I, et al. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 2011; 378:1316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muriuki JM, Mentzer AJ, Mitchell R, et al. Malaria is a cause of iron deficiency in African children. Nat Med 2021; 27:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uyoga S, Macharia AW, Ndila CM, et al. The indirect health effects of malaria estimated from health advantages of the sickle cell trait. Nat Commun 2019; 10:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams TN, Mwangi TW, Wambua S, et al. Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait. Nat Genet 2005; 37:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel JC, Mwapasa V, Kalilani L, et al. Absence of Association Between Sickle Trait Hemoglobin and Placental Malaria Outcomes. Am J Trop Med Hyg 2016; 94:1002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gong L, Maiteki-Sebuguzi C, Rosenthal PJ, et al. Evidence for both innate and acquired mechanisms of protection from Plasmodium falciparum in children with sickle cell trait. Blood 2012; 119:3808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bunn HF. The triumph of good over evil: protection by the sickle gene against malaria. Blood 2013; 121:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaMonte G, Philip N, Reardon J, et al. Translocation of sickle cell erythrocyte microRNAs into Plasmodium falciparum inhibits parasite translation and contributes to malaria resistance. Cell Host Microbe 2012; 12:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman MJ, Roth EF, Nagel RL, Trager W. Plasmodium falciparum: physiological interactions with the human sickle cell. Exp Parasitol 1979; 47:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cappadoro M, Giribaldi G, O'Brien E, et al. Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood 1998; 92:2527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diakité SA, Ndour PA, Brousse V, et al. Stage-dependent fate of Plasmodium falciparum-infected red blood cells in the spleen and sickle-cell trait-related protection against malaria. Malar J 2016; 15:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cyrklaff M, Sanchez CP, Kilian N, et al. Hemoglobins S and C interfere with actin remodeling in Plasmodium falciparum-infected erythrocytes. Science 2011; 334:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kilian N, Dittmer M, Cyrklaff M, et al. Haemoglobin S and C affect the motion of Maurer's clefts in Plasmodium falciparum-infected erythrocytes. Cell Microbiol 2013; 15:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cyrklaff M, Srismith S, Nyboer B, et al. Oxidative insult can induce malaria-protective trait of sickle and fetal erythrocytes. Nat Commun 2016; 7:13401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cholera R, Brittain NJ, Gillrie MR, et al. Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin. Proc Natl Acad Sci U S A 2008; 105:991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Opi DH, Ochola LB, Tendwa M, et al. Mechanistic Studies of the Negative Epistatic Malaria-protective Interaction Between Sickle Cell Trait and α(+)thalassemia. EBioMedicine 2014; 1:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guggenmoos-Holzmann I, Bienzle U, Luzzatto L. Plasmodium falciparum malaria and human red cells. II. Red cell genetic traits and resistance against malaria. Int J Epidemiol 1981; 10:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Band G, Leffler EM, Jallow M, et al. Malaria protection due to sickle haemoglobin depends on parasite genotype. Nature 2022; 602:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roth EF Jr, Friedman M, Ueda Y, et al. Sickling rates of human AS red cells infected in vitro with Plasmodium falciparum malaria. Science 1978; 202:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luzzatto L, Nwachuku-Jarrett ES, Reddy S. Increased sickling of parasitised erythrocytes as mechanism of resistance against malaria in the sickle-cell trait. Lancet 1970; 1:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasvol G, Weatherall DJ, Wilson RJ. Cellular mechanism for the protective effect of haemoglobin S against P. falciparum malaria. Nature 1978; 274:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasvol G. The interaction between sickle haemoglobin and the malarial parasite Plasmodium falciparum. Trans R Soc Trop Med Hyg 1980; 74:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olson JA, Nagel RL. Synchronized cultures of P falciparum in abnormal red cells: the mechanism of the inhibition of growth in HbCC cells. Blood 1986; 67:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman MJ. Erythrocytic mechanism of sickle cell resistance to malaria. Proc Natl Acad Sci U S A 1978; 75:1994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Archer NM, Petersen N, Clark MA, et al. Resistance to Plasmodium falciparum in sickle cell trait erythrocytes is driven by oxygen-dependent growth inhibition. Proc Natl Acad Sci U S A 2018; 115:7350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olivieri O, Vitoux D, Galacteros F, et al. Hemoglobin variants and activity of the (K+Cl-) cotransport system in human erythrocytes. Blood 1992; 79:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lew VL, Ortiz OE, Bookchin RM. Stochastic nature and red cell population distribution of the sickling-induced Ca2+ permeability. J Clin Invest 1997; 99:2727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz RS, Musto S, Fabry ME, Nagel RL. Two distinct pathways mediate the formation of intermediate density cells and hyperdense cells from normal density sickle red blood cells. Blood 1998; 92:4844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ginsburg H, Handeli S, Friedman S, et al. Effects of red blood cell potassium and hypertonicity on the growth of Plasmodium falciparum in culture. Z Parasitenkd 1986; 72:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanabe K, Izumo A, Kageyama K. Growth of Plasmodium falciparum in sodium-enriched human erythrocytes. Am J Trop Med Hyg 1986; 35:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petersen JEV, Saelens JW, Freedman E, et al. Sickle-trait hemoglobin reduces adhesion to both CD36 and EPCR by Plasmodium falciparum-infected erythrocytes. PLoS Pathog 2021; 17:e1009659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lansche C, Dasanna AK, Quadt K, et al. The sickle cell trait affects contact dynamics and endothelial cell activation in Plasmodium falciparum-infected erythrocytes. Commun Biol 2018; 1:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayoumi RA. The sickle-cell trait modifies the intensity and specificity of the immune response against P. falciparum malaria and leads to acquired protective immunity. Med Hypotheses 1987; 22:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayoumi RA. Does the mechanism of protection from falciparum malaria by red cell genetic disorders involve a switch to a balanced TH1/TH2 cytokine production mode? Med Hypotheses 1997; 48:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           EDOZIEN JC, BOYO AE, MORLEY DC. The relationship of serum gamma-globulin concentration to malaria and sickling. J Clin Pathol 1960; 13:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornille-Brøgger R, Fleming AF, Kagan I, et al. Abnormal haemoglobins in the Sudan savanna of Nigeria. II. Immunological response to malaria in normals and subjects with sickle cell trait. Ann Trop Med Parasitol 1979; 73:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan X, Traore B, Kayentao K, et al. Hemoglobin S and C heterozygosity enhances neither the magnitude nor breadth of antibody responses to a diverse array of Plasmodium falciparum antigens. J Infect Dis 2011; 204:1750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Zeid YA, Abdulhadi NH, Theander TG, et al. Seasonal changes in cell mediated immune responses to soluble Plasmodium falciparum antigens in children with haemoglobin AA and haemoglobin AS. Trans R Soc Trop Med Hyg 1992; 86:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarzer E, Turrini F, Ulliers D, et al. Impairment of macrophage functions after ingestion of Plasmodium falciparum-infected erythrocytes or isolated malarial pigment. J Exp Med 1992; 176:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urban BC, Ferguson DJ, Pain A, et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 1999; 400:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGilvray ID, Serghides L, Kapus A, et al. Nonopsonic monocyte/macrophage phagocytosis of Plasmodium falciparum-parasitized erythrocytes: a role for CD36 in malarial clearance. Blood 2000; 96:3231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabry ME, Nagel RL, Pachnis A, et al. High expression of human beta S- and alpha-globins in transgenic mice: hemoglobin composition and hematological consequences. Proc Natl Acad Sci U S A 1992; 89:12150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabry ME, Costantini F, Pachnis A, et al. High expression of human beta S- and alpha-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia. Proc Natl Acad Sci U S A 1992; 89:12155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagel RL. A knockout of a transgenic mouse--animal models of sickle cell anemia. N Engl J Med 1998; 339:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serjeant GR. Mortality from sickle cell disease in Africa. BMJ 2005; 330:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diallo D, Tchernia G. Sickle cell disease in Africa. Curr Opin Hematol 2002; 9:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAuley CF, Webb C, Makani J, et al. High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya. Blood 2010; 116:1663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connon R, George EC, Olupot-Olupot P, et al. Incidence and predictors of hospital readmission in children presenting with severe anaemia in Uganda and Malawi: a secondary analysis of TRACT trial data. BMC Public Health 2021; 21:1480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makani J, Komba AN, Cox SE, et al. Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. Blood 2010; 115:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diop S, Soudré F, Seck M, et al. Sickle-cell disease and malaria: evaluation of seasonal intermittent preventive treatment with sulfadoxine-pyrimethamine in Senegalese patients-a randomized placebo-controlled trial. Ann Hematol 2011; 90:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oniyangi O, Omari AA. Malaria chemoprophylaxis in sickle cell disease. Cochrane Database Syst Rev 2019; 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreuels B, Kreuzberg C, Kobbe R, et al. Differing effects of HbS and HbC traits on uncomplicated falciparum malaria, anemia, and child growth. Blood 2010; 115:4551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travassos MA, Coulibaly D, Laurens MB, et al. Hemoglobin C Trait Provides Protection From Clinical Falciparum Malaria in Malian Children. J Infect Dis 2015; 212:1778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modiano D, Luoni G, Sirima BS, et al. Haemoglobin C protects against clinical Plasmodium falciparum malaria. Nature 2001; 414:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mockenhaupt FP, Ehrhardt S, Cramer JP, et al. Hemoglobin C and resistance to severe malaria in Ghanaian children. J Infect Dis 2004; 190:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopera-Mesa TM, Doumbia S, Konaté D, et al. Effect of red blood cell variants on childhood malaria in Mali: a prospective cohort study. Lancet Haematol 2015; 2:e140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tétard M, Milet J, Dechavanne S, et al. Heterozygous HbAC but not HbAS is associated with higher newborn birthweight among women with pregnancy-associated malaria. Sci Rep 2017; 7:1414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fairhurst RM, Baruch DI, Brittain NJ, et al. Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. Nature 2005; 435:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kilian N, Srismith S, Dittmer M, et al. Hemoglobin S and C affect protein export in Plasmodium falciparum-infected erythrocytes. Biol Open 2015; 4:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman MJ, Roth EF, Nagel RL, Trager W. The role of hemoglobins C, S, and Nbalt in the inhibition of malaria parasite development in vitro. Am J Trop Med Hyg 1979; 28:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin MJ, Nagel RL, Hirsch RE. Acceleration of hemoglobin C crystallization by hemoglobin S. Blood 1989; 74:1823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penman BS, Pybus OG, Weatherall DJ, Gupta S. Epistatic interactions between genetic disorders of hemoglobin can explain why the sickle-cell gene is uncommon in the Mediterranean. Proc Natl Acad Sci U S A 2009; 106:21242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brittenham G, Lozoff B, Harris JW, et al. Thalassemia in southern India. Interaction of genes for beta+-, beta o-, and delta o beta o-thalassemia. Acta Haematol 1980; 63:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulozik AE, Kar BC, Serjeant GR, et al. The molecular basis of alpha thalassemia in India. Its interaction with the sickle cell gene. Blood 1988; 71:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labie D, Srinivas R, Dunda O, et al. Haplotypes in tribal Indians bearing the sickle gene: evidence for the unicentric origin of the beta S mutation and the unicentric origin of the tribal populations of India. Hum Biol 1989; 61:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modiano G, Morpurgo G, Terrenato L, et al. Protection against malaria morbidity: near-fixation of the alpha-thalassemia gene in a Nepalese population. Am J Hum Genet 1991; 48:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrenato L, Shrestha S, Dixit KA, et al. Decreased malaria morbidity in the Tharu people compared to sympatric populations in Nepal. Ann Trop Med Parasitol 1988; 82:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flint J, Hill AV, Bowden DK, et al. High frequencies of alpha-thalassaemia are the result of natural selection by malaria. Nature 1986; 321:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yenchitsomanus P, Summers KM, Board PG, et al. Alpha-thalassemia in Papua New Guinea. Hum Genet 1986; 74:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mockenhaupt FP, Ehrhardt S, Gellert S, et al. Alpha(+)-thalassemia protects African children from severe malaria. Blood 2004; 104:2003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen SJ, O'Donnell A, Alexander ND, et al. alpha+-Thalassemia protects children against disease caused by other infections as well as malaria. Proc Natl Acad Sci U S A 1997; 94:14736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams TN, Wambua S, Uyoga S, et al. Both heterozygous and homozygous alpha+ thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. Blood 2005; 106:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wambua S, Mwangi TW, Kortok M, et al. The effect of alpha+-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya. PLoS Med 2006; 3:e158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siniscalco M, Bernini L, Latte B, Motulski AG. Favism and thalassaemia in Sardinia and their relationship to malaria. Nature 1961; 190:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill AV, Bowden DK, O'Shaughnessy DF, et al. Beta thalassemia in Melanesia: association with malaria and characterization of a common variant (IVS-1 nt 5 G----C). Blood 1988; 72:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atamna H, Ginsburg H. The malaria parasite supplies glutathione to its host cell--investigation of glutathione transport and metabolism in human erythrocytes infected with Plasmodium falciparum. Eur J Biochem 1997; 250:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allison AC, Eugui EM. A radical interpretation of immunity to malaria parasites. Lancet 1982; 2:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allison AC, Eugui EM. The role of cell-mediated immune responses in resistance to malaria, with special reference to oxidant stress. Annu Rev Immunol 1983; 1:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glushakova S, Balaban A, McQueen PG, et al. Hemoglobinopathic erythrocytes affect the intraerythrocytic multiplication of Plasmodium falciparum in vitro. J Infect Dis 2014; 210:1100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brockelman CR, Wongsattayanont B, Tan-ariya P, Fucharoen S. Thalassemic erythrocytes inhibit in vitro growth of Plasmodium falciparum. J Clin Microbiol 1987; 25:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pattanapanyasat K, Yongvanitchit K, Tongtawe P, et al. Impairment of Plasmodium falciparum growth in thalassemic red blood cells: further evidence by using biotin labeling and flow cytometry. Blood 1999; 93:3116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasvol G, Weatherall DJ, Wilson RJ, et al. Fetal haemoglobin and malaria. Lancet 1976; 1:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasvol G, Weatherall DJ, Wilson RJ. Effects of foetal haemoglobin on susceptibility of red cells to Plasmodium falciparum. Nature 1977; 270:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roth EF Jr, Shear HL, Costantini F, et al. Malaria in beta-thalassemic mice and the effects of the transgenic human beta-globin gene and splenectomy. J Lab Clin Med 1988; 111:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clegg JB, Weatherall DJ. Thalassemia and malaria: new insights into an old problem. Proc Assoc Am Physicians 1999; 111:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams TN, Maitland K, Bennett S, et al. High incidence of malaria in alpha-thalassaemic children. Nature 1996; 383:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krause MA, Diakite SA, Lopera-Mesa TM, et al. α-Thalassemia impairs the cytoadherence of Plasmodium falciparum-infected erythrocytes. PLoS One 2012; 7:e37214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowkes FJ, Allen SJ, Allen A, et al. Increased microerythrocyte count in homozygous alpha(+)-thalassaemia contributes to protection against severe malarial anaemia. PLoS Med 2008; 5:e56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veenemans J, Andang'o PE, Mbugi EV, et al. Alpha+ -thalassemia protects against anemia associated with asymptomatic malaria: evidence from community-based surveys in Tanzania and Kenya. J Infect Dis 2008; 198:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atkinson SH, Uyoga SM, Nyatichi E, et al. Epistasis between the haptoglobin common variant and α+thalassemia influences risk of severe malaria in Kenyan children. Blood 2014; 123:2008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flatz G. Hemoglobin E: distribution and population dynamics. Humangenetik 1967; 3:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sicard D, Lieurzou Y, Lapoumeroulie C, Labie D. High genetic polymorphism of hemoglobin disorders in Laos. Complex phenotypes due to associated thalassemic syndromes. Hum Genet 1979; 50:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vernes AJ, Haynes JD, Tang DB, et al. Decreased growth of Plasmodium falciparum in red cells containing haemoglobin E, a role for oxidative stress, and a sero-epidemiological correlation. Trans R Soc Trop Med Hyg 1986; 80:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagel RL, Raventos-Suarez C, Fabry ME, et al. Impairment of the growth of Plasmodium falciparum in HbEE erythrocytes. J Clin Invest 1981; 68:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chotivanich K, Udomsangpetch R, Pattanapanyasat K, et al. Hemoglobin E: a balanced polymorphism protective against high parasitemias and thus severe P falciparum malaria. Blood 2002; 100:1172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frischer H, Bowman J. Hemoglobin E, an oxidatively unstable mutation. J Lab Clin Med 1975; 85:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Archer NM, Petersen N, Duraisingh MT. Fetal hemoglobin does not inhibit Plasmodium falciparum growth. Blood Adv 2019; 3:2149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman MJ. Oxidant damage mediates variant red cell resistance to malaria. Nature 1979; 280:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shear HL, Grinberg L, Gilman J, et al. Transgenic mice expressing human fetal globin are protected from malaria by a novel mechanism. Blood 1998; 92:2520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaul DK, Nagel RL, Llena JF, Shear HL. Cerebral malaria in mice: demonstration of cytoadherence of infected red blood cells and microrheologic correlates. Am J Trop Med Hyg 1994; 50:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Min-Oo G, Fortin A, Tam MF, et al. Pyruvate kinase deficiency in mice protects against malaria. Nat Genet 2003; 35:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayi K, Min-Oo G, Serghides L, et al. Pyruvate kinase deficiency and malaria. N Engl J Med 2008; 358:1805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machado P, Manco L, Gomes C, et al. Pyruvate kinase deficiency in sub-Saharan Africa: identification of a highly frequent missense mutation (G829A;Glu277Lys) and association with malaria. PLoS One 2012; 7:e47071.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7099 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6038684" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Sickle-cell trait in human biological and cultural evolution. Development of agriculture causing increased malaria is bound to gene-pool changes causing malaria reduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3901257" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15114532" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Extended linkage disequilibrium surrounding the hemoglobin E variant due to malarial selection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15035005" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The origin of malaria: mixed messages from genetic diversity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27381764" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Out of Africa: origins and evolution of the human malaria parasites Plasmodium falciparum and Plasmodium vivax.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20864995" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Origin of the human malaria parasite Plasmodium falciparum in gorillas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30827499" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Recent Adaptive Acquisition by African Rainforest Hunter-Gatherers of the Late Pleistocene Sickle-Cell Mutation Suggests Past Differences in Malaria Exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26047685" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The evolutionary origins of Southeast Asian Ovalocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29526279" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Whole-Genome-Sequence-Based Haplotypes Reveal Single Origin of the Sickle Allele during the Holocene Wet Phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29526279" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Whole-Genome-Sequence-Based Haplotypes Reveal Single Origin of the Sickle Allele during the Holocene Wet Phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Disease and Evolution
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13115700" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Protection afforded by sickle-cell trait against subtertian malareal infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17519411" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Hemoglobin variants and disease manifestations in severe falciparum malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11965279" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Protective effects of the sickle cell gene against malaria morbidity and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8462981" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Why are some genetic diseases common? Distinguishing selection from other processes by molecular analysis of globin gene variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11035799" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Quantifying genetic and nongenetic contributions to malarial infection in a Sri Lankan population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16259530" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Heritability of malaria in Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32130487" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Human genetics and malaria resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/105074" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Interaction between cytochalasin B-treated malarial parasites and erythrocytes. Attachment and junction formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30753425" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Targeting malaria parasite invasion of red blood cells as an antimalarial strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8009226" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19563830" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Molecular basis of binding of the Plasmodium falciparum receptor BAEBL to erythrocyte receptor glycophorin C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31234897" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Erythrocyte glycophorins as receptors for Plasmodium merozoites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35433504" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The Cellular and Molecular Interaction Between Erythrocytes and Plasmodium falciparum Merozoites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8046329" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1496004" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A family of erythrocyte binding proteins of malaria parasites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30033078" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3101355" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Increased phagocytosis of Plasmodium falciparum-infected erythrocytes with haemoglobin E by peripheral blood monocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3281435" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Impaired parasite growth and increased susceptibility to phagocytosis of Plasmodium falciparum infected alpha-thalassemia or hemoglobin Constant Spring red blood cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15280204" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8417791" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Transgenic mice expressing human sickle hemoglobin are partially resistant to rodent malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1865923" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Common west African HLA antigens are associated with protection from severe malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1280333" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Molecular analysis of the association of HLA-B53 and resistance to severe malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2665857" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Abnormalities in the mechanical properties of red blood cells caused by Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8228577" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Membrane rigidity of red blood cells parasitized by different strains of Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35676275" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The impact of malaria-protective red blood cell polymorphisms on parasite biomass in children with severe Plasmodium falciparum malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7833466" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The coding sequence of Duffy blood group gene in humans and simians: restriction fragment length polymorphism, antibody and malarial parasite specificities, and expression in nonerythroid tissues in Duffy-negative individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6695171" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Identification of an erythrocyte component carrying the Duffy blood group Fya antigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2668273" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Purification and characterization of an erythrocyte membrane protein complex carrying Duffy blood group antigenicity. Possible receptor for Plasmodium vivax and Plasmodium knowlesi malaria parasite.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7663520" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/339418" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The Duffy blood group and malaria prevalence in Gambian West Africans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/115155" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The Duffy blood group system in Israeli Jews and Arabs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10570183" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Emergence of FY*A(null) in a Plasmodium vivax-endemic region of Papua New Guinea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35256675" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Prevalence and risk of Plasmodium vivax infection among Duffy-negative individuals: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22123959" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13252508" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Experimental testing of the immunity of Negroes to Plasmodium vivax.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/778616" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1145213" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2680568" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Plasmodium vivax interaction with the human Duffy blood group glycoprotein: identification of a parasite receptor-like protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2469769" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : In vitro evaluation of the role of the Duffy blood group in erythrocyte invasion by Plasmodium vivax.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7689250" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8879225" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23224555" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7960140" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Natural variation within the principal adhesion domain of the Plasmodium vivax duffy binding protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10570199" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Mapping regions containing binding residues within functional domains of Plasmodium vivax and Plasmodium knowlesi erythrocyte-binding proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24415938" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11279211" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax duffy-binding protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31133755" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28614791" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31092602" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23916294" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37437014" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28226242" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Plasmodium falciparum ligand binding to erythrocytes induce alterations in deformability essential for invasion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/327014" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Evidence for differences in erythrocyte surface receptors for the malarial parasites, Plasmodium falciparum and Plasmodium knowlesi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7026577" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Inhibitory effects of erythrocyte membrane proteins on the in vitro invasion of the human malarial parasite (Plasmodium falciparum) into its host cell.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6194114" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Role of internal domains of glycophorin in Plasmodium falciparum invasion of human erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6373782" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Recognition and invasion of human erythrocytes by malarial parasites: contribution of sialoglycoproteins to attachment and host specificity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6127459" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Glycophorin as a possible receptor for Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7040988" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Erythrocytes deficiency in glycophorin resist invasion by the malarial parasite Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6200133" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Susceptibility to invasion by Plasmodium falciparum of some human erythrocytes carrying rare blood group antigens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5637830" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Genetical polymorphisms and the incidence of disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28760933" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Genetic Evidence for Erythrocyte Receptor Glycophorin B Expression Levels Defining a Dominant Plasmodium falciparum Invasion Pathway into Human Erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19279206" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Glycophorin B is the erythrocyte receptor of Plasmodium falciparum erythrocyte-binding ligand, EBL-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3308959" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Falciparum malaria parasites invade erythrocytes that lack glycophorin A and B (MkMk). Strain differences indicate receptor heterogeneity and two pathways for invasion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26416757" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : A novel locus of resistance to severe malaria in a region of ancient balancing selection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28522690" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Resistance to malaria through structural variation of red blood cell invasion receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8112738" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Glycophorin variants and Plasmodium falciparum: protective effect of the Dantu phenotype in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32939086" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Red blood cell tension protects against severe malaria in the Dantu blood group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12469115" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2750321" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A selective advantage for the Gerbich-negative phenotype in malarious areas of Papua New Guinea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11719395" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The association of the glycophorin C exon 3 deletion with ovalocytosis and malaria susceptibility in the Wosera, Papua New Guinea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7579415" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Role of the Plasmodium falciparum mature-parasite-infected erythrocyte surface antigen (MESA/PfEMP-2) in malarial infection of erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8605365" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Reduced invasion and growth of Plasmodium falciparum into elliptocytic red blood cells with a combined deficiency of protein 4.1, glycophorin C, and p55.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12576308" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Glycophorin C is the receptor for the Plasmodium falciparum erythrocyte binding ligand PfEBP-2 (baebl).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10446142" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Mapping the binding domains involved in the interaction between the Plasmodium falciparum knob-associated histidine-rich protein (KAHRP) and the cytoadherence ligand P. falciparum erythrocyte membrane protein 1 (PfEMP1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11698301" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Plasmodium falciparum erythrocyte membrane protein 1 functions as a ligand for P-selectin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18003641" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22909232" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Cytoadherence in paediatric malaria: ABO blood group, CD36, and ICAM1 expression and severe Plasmodium falciparum infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9452303" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Short report: severe malaria associated with blood group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10825041" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : The role of red blood cell polymorphisms in resistance and susceptibility to malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1402677" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Plasmodium falciparum erythrocyte rosetting is mediated by promiscuous lectin-like interactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10768996" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Blood group A antigen is a coreceptor in Plasmodium falciparum rosetting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8260712" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Alteration in cytoadherence and rosetting of Plasmodium falciparum-infected thalassemic red blood cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7768616" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Plasmodium falciparum rosetting is associated with malaria severity in Kenya.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9614453" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Rosetting characteristics of uninfected erythrocytes from healthy individuals and malaria patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17959777" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23071435" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : ABO blood groups influence macrophage-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19704115" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : ABO blood group glycans modulate sialic acid recognition on erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32360095" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : ABO blood group should be considered and reported when red blood cell exchange transfusion is used to treat Plasmodiumfalciparum Malaria patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11313284" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Molecular identification of Knops blood group polymorphisms found in long homologous region D of complement receptor 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16277654" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Complement receptor 1 polymorphisms associated with resistance to severe malaria in Kenya.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25916414" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Severity of malaria in relation to a complement receptor 1 polymorphism: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29690995" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Two complement receptor one alleles have opposing associations with cerebral malaria and interact withα+thalassaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24200236" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Human genetic polymorphisms in the Knops blood group are not associated with a protective advantage against Plasmodium falciparum malaria in Southern Ghana.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20585558" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Complement receptor 1 is a sialic acid-independent erythrocyte receptor of Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31221984" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Complement Receptor 1 availability on red blood cell surface modulates Plasmodium vivax invasion of human reticulocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21685372" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9230440" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22080952" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30542156" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Structure of Plasmodium falciparum Rh5-CyRPA-Ripr invasion complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28409866" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : P. falciparum RH5-Basigin interaction induces changes in the cytoskeleton of the host RBC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24297912" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : RH5-Basigin interaction plays a major role in the host tropism of Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24293631" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26195724" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Basigin is a druggable target for host-oriented antimalarial interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22895189" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Genome-wide association study indicates two novel resistance loci for severe malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28714864" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : An erythroid-specific ATP2B4 enhancer mediates red blood cell hydration and malaria susceptibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29599243" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Erythrocytic ferroportin reduces intracellular iron accumulation, hemolysis, and malaria risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31517041" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15728121" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : The hydration state of human red blood cells and their susceptibility to invasion by Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29576450" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Common PIEZO1 Allele in African Populations Causes RBC Dehydration and Attenuates Plasmodium Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1832936" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Resistance to malaria in ankyrin and spectrin deficient mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/328370" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Malaria and hereditary ovalocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22973182" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8524388" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Ovalocytosis and cerebral malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9633878" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Red cell morphology and malaria anaemia in children with Southeast-Asian ovalocytosis band 3 in Papua New Guinea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7029547" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Ovalocytic erythrocytes from Melanesians are resistant to invasion by malaria parasites in culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6338046" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Resistance of Melanesian elliptocytes (ovalocytes) to invasion by Plasmodium knowlesi and Plasmodium falciparum malaria parasites in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9640598" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Malaria protection in hereditary ovalocytosis: relation to red cell deformability, red cell parameters and degree of ovalocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6630511" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : A monoclonal antibody to rhesus erythrocyte band 3 inhibits invasion by malaria (Plasmodium knowlesi) merozoites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6722355" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Rigid membranes of Malayan ovalocytes: a likely genetic barrier against malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2661709" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Increased ovalocytic red cells and their low parasitemia in malaria infected subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2233937" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Red-cell cytoskeletal abnormalities--implications for malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8857939" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Epidemiological studies of spectrin mutations related to hereditary elliptocytosis and spectrin polymorphisms in Benin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17414207" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Spectrin-based skeleton in red blood cells and malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8211226" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : The red blood cell and malaria parasite invasion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2205856" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Growth of Plasmodium falciparum in human erythrocytes containing abnormal membrane proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8193370" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Phosphorylation of protein 4.1 in Plasmodium falciparum-infected human red blood cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19179303" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Novel roles for erythroid Ankyrin-1 revealed through an ENU-induced null mouse mutant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22445352" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21027890" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Sickle cell disease in the Balovale District of Northern Rhodesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14278460" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : POLYMORPHISM AND NATURAL SELECTION IN HUMAN POPULATIONS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6357119" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Falciparum malaria and beta-thalassaemia trait in northern Liberia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/315211" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Abnormal haemoglobins in the Sudan savanna of Nigeria. I. Prevalence of haemoglobins and relationships between sickle cell trait, malaria and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2694458" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2068750" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Differential antibody response of Gambian donors to soluble Plasmodium falciparum antigens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26445879" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Quantitative trait locus analysis of parasite density reveals that HbS gene carriage protects severe malaria patients against Plasmodium falciparum hyperparasitaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21903251" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33619371" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Malaria is a cause of iron deficiency in African children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30787300" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : The indirect health effects of malaria estimated from health advantages of the sickle cell trait.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16227994" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27001763" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Absence of Association Between Sickle Trait Hemoglobin and Placental Malaria Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22327223" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Evidence for both innate and acquired mechanisms of protection from Plasmodium falciparum in children with sickle cell trait.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23118217" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : The triumph of good over evil: protection by the sickle gene against malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22901539" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Translocation of sickle cell erythrocyte microRNAs into Plasmodium falciparum inhibits parasite translation and contributes to malaria resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33821" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Plasmodium falciparum: physiological interactions with the human sickle cell.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9746794" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27655345" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Stage-dependent fate of Plasmodium falciparum-infected red blood cells in the spleen and sickle-cell trait-related protection against malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22075726" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Hemoglobins S and C interfere with actin remodeling in Plasmodium falciparum-infected erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23279197" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Haemoglobin S and C affect the motion of Maurer's clefts in Plasmodium falciparum-infected erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27824335" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Oxidative insult can induce malaria-protective trait of sickle and fetal erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18192399" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25893206" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Mechanistic Studies of the Negative Epistatic Malaria-protective Interaction Between Sickle Cell Trait andα(+)thalassemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7016776" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Plasmodium falciparum malaria and human red cells. II. Red cell genetic traits and resistance against malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34883497" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Malaria protection due to sickle haemoglobin depends on parasite genotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/360396" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Sickling rates of human AS red cells infected in vitro with Plasmodium falciparum malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4189578" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Increased sickling of parasitised erythrocytes as mechanism of resistance against malaria in the sickle-cell trait.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/353566" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Cellular mechanism for the protective effect of haemoglobin S against P. falciparum malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7010693" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : The interaction between sickle haemoglobin and the malarial parasite Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3513872" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Synchronized cultures of P falciparum in abnormal red cells: the mechanism of the inhibition of growth in HbCC cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/347452" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Erythrocytic mechanism of sickle cell resistance to malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29946035" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Resistance to Plasmodium falciparum in sickle cell trait erythrocytes is driven by oxygen-dependent growth inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1732017" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Hemoglobin variants and activity of the (K+Cl-) cotransport system in human erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9169503" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Stochastic nature and red cell population distribution of the sickling-induced Ca2+ permeability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9845552" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Two distinct pathways mediate the formation of intermediate density cells and hyperdense cells from normal density sickle red blood cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3518266" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Effects of red blood cell potassium and hypertonicity on the growth of Plasmodium falciparum in culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3518504" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Growth of Plasmodium falciparum in sodium-enriched human erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34115805" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Sickle-trait hemoglobin reduces adhesion to both CD36 and EPCR by Plasmodium falciparum-infected erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30534603" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : The sickle cell trait affects contact dynamics and endothelial cell activation in Plasmodium falciparum-infected erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3295496" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : The sickle-cell trait modifies the intensity and specificity of the immune response against P. falciparum malaria and leads to acquired protective immunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9049983" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Does the mechanism of protection from falciparum malaria by red cell genetic disorders involve a switch to a balanced TH1/TH2 cytokine production mode?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13819366" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : The relationship of serum gamma-globulin concentration to malaria and sickling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/386969" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Abnormal haemoglobins in the Sudan savanna of Nigeria. II. Immunological response to malaria in normals and subjects with sickle cell trait.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21998476" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Hemoglobin S and C heterozygosity enhances neither the magnitude nor breadth of antibody responses to a diverse array of Plasmodium falciparum antigens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1566293" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Seasonal changes in cell mediated immune responses to soluble Plasmodium falciparum antigens in children with haemoglobin AA and haemoglobin AS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1402649" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Impairment of macrophage functions after ingestion of Plasmodium falciparum-infected erythrocytes or isolated malarial pigment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10403251" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11050008" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Nonopsonic monocyte/macrophage phagocytosis of Plasmodium falciparum-parasitized erythrocytes: a role for CD36 in malarial clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1465454" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : High expression of human beta S- and alpha-globins in transgenic mice: hemoglobin composition and hematological consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1465455" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : High expression of human beta S- and alpha-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9664098" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : A knockout of a transgenic mouse--animal models of sickle cell anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15731125" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Mortality from sickle cell disease in Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11844993" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Sickle cell disease in Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20530796" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34325680" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Incidence and predictors of hospital readmission in children presenting with severe anaemia in Uganda and Malawi: a secondary analysis of TRACT trial data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19901265" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20694469" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : Sickle-cell disease and malaria: evaluation of seasonal intermittent preventive treatment with sulfadoxine-pyrimethamine in Senegalese patients-a randomized placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31681984" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : Malaria chemoprophylaxis in sickle cell disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20231425" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : Differing effects of HbS and HbC traits on uncomplicated falciparum malaria, anemia, and child growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26019283" id="rid198" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          199 : Hemoglobin C Trait Provides Protection From Clinical Falciparum Malaria in Malian Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11713529" id="rid199" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          200 : Haemoglobin C protects against clinical Plasmodium falciparum malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15295709" id="rid200" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          201 : Hemoglobin C and resistance to severe malaria in Ghanaian children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26687956" id="rid201" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          202 : Effect of red blood cell variants on childhood malaria in Mali: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28469130" id="rid202" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          203 : Heterozygous HbAC but not HbAS is associated with higher newborn birthweight among women with pregnancy-associated malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15973412" id="rid203" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          204 : Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25701664" id="rid204" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          205 : Hemoglobin S and C affect protein export in Plasmodium falciparum-infected erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/384816" id="rid205" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          206 : The role of hemoglobins C, S, and Nbalt in the inhibition of malaria parasite development in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2790206" id="rid206" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          207 : Acceleration of hemoglobin C crystallization by hemoglobin S.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19955437" id="rid207" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          208 : Epistatic interactions between genetic disorders of hemoglobin can explain why the sickle-cell gene is uncommon in the Mediterranean.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6154398" id="rid208" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          209 : Thalassemia in southern India. Interaction of genes for beta+-, beta o-, and delta o beta o-thalassemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2827816" id="rid209" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          210 : The molecular basis of alpha thalassemia in India. Its interaction with the sickle cell gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2480325" id="rid210" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          211 : Haplotypes in tribal Indians bearing the sickle gene: evidence for the unicentric origin of the beta S mutation and the unicentric origin of the tribal populations of India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1990845" id="rid211" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          212 : Protection against malaria morbidity: near-fixation of the alpha-thalassemia gene in a Nepalese population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3041928" id="rid212" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          213 : Decreased malaria morbidity in the Tharu people compared to sympatric populations in Nepal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3713863" id="rid213" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          214 : High frequencies of alpha-thalassaemia are the result of natural selection by malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2878871" id="rid214" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          215 : Alpha-thalassemia in Papua New Guinea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15198952" id="rid215" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          216 : Alpha(+)-thalassemia protects African children from severe malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9405682" id="rid216" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          217 : alpha+-Thalassemia protects children against disease caused by other infections as well as malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15769889" id="rid217" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          218 : Both heterozygous and homozygous alpha+ thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16605300" id="rid218" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          219 : The effect of alpha+-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid219" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          220 : Favism and thalassaemia in Sardinia and their relationship to malaria
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2898955" id="rid220" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          221 : Beta thalassemia in Melanesia: association with malaria and characterization of a common variant (IVS-1 nt 5 G----C).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9461289" id="rid221" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          222 : The malaria parasite supplies glutathione to its host cell--investigation of glutathione transport and metabolism in human erythrocytes infected with Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6129509" id="rid222" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          223 : A radical interpretation of immunity to malaria parasites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6100538" id="rid223" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          224 : The role of cell-mediated immune responses in resistance to malaria, with special reference to oxidant stress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24688070" id="rid224" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          225 : Hemoglobinopathic erythrocytes affect the intraerythrocytic multiplication of Plasmodium falciparum in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3539999" id="rid225" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          226 : Thalassemic erythrocytes inhibit in vitro growth of Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10216109" id="rid226" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          227 : Impairment of Plasmodium falciparum growth in thalassemic red blood cells: further evidence by using biotin labeling and flow cytometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/73695" id="rid227" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          228 : Fetal haemoglobin and malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/337159" id="rid228" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          229 : Effects of foetal haemoglobin on susceptibility of red cells to Plasmodium falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3335824" id="rid229" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          230 : Malaria in beta-thalassemic mice and the effects of the transgenic human beta-globin gene and splenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10417734" id="rid230" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          231 : Thalassemia and malaria: new insights into an old problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8849722" id="rid231" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          232 : High incidence of malaria in alpha-thalassaemic children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22623996" id="rid232" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          233 : α-Thalassemia impairs the cytoadherence of Plasmodium falciparum-infected erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18351796" id="rid233" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          234 : Increased microerythrocyte count in homozygous alpha(+)-thalassaemia contributes to protection against severe malarial anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18582194" id="rid234" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          235 : Alpha+ -thalassemia protects against anemia associated with asymptomatic malaria: evidence from community-based surveys in Tanzania and Kenya.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24478401" id="rid235" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          236 : Epistasis between the haptoglobin common variant andα+thalassemia influences risk of severe malaria in Kenyan children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6074385" id="rid236" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          237 : Hemoglobin E: distribution and population dynamics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/489017" id="rid237" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          238 : High genetic polymorphism of hemoglobin disorders in Laos. Complex phenotypes due to associated thalassemic syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3544362" id="rid238" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          239 : Decreased growth of Plasmodium falciparum in red cells containing haemoglobin E, a role for oxidative stress, and a sero-epidemiological correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7019245" id="rid239" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          240 : Impairment of the growth of Plasmodium falciparum in HbEE erythrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12149194" id="rid240" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          241 : Hemoglobin E: a balanced polymorphism protective against high parasitemias and thus severe P falciparum malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1120926" id="rid241" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          242 : Hemoglobin E, an oxidatively unstable mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31311778" id="rid242" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          243 : Fetal hemoglobin does not inhibit Plasmodium falciparum growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/377105" id="rid243" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          244 : Oxidant damage mediates variant red cell resistance to malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9746793" id="rid244" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          245 : Transgenic mice expressing human fetal globin are protected from malaria by a novel mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8166359" id="rid245" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          246 : Cerebral malaria in mice: demonstration of cytoadherence of infected red blood cells and microrheologic correlates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14595440" id="rid246" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          247 : Pyruvate kinase deficiency in mice protects against malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18420493" id="rid247" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          248 : Pyruvate kinase deficiency and malaria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23082140" id="rid248" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          249 : Pyruvate kinase deficiency in sub-Saharan Africa: identification of a highly frequent missense mutation (G829A;Glu277Lys) and association with malaria.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
